[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BIOTECHSCANNER BIOTECH SCANNER BIOTECH SCANNER posts on X about $iova, $aqst, $nklr, $gsrt the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::1408278003109466115/interactions)  - X Week XXXXXX -XX% - X Month XXXXXXX +273% - X Months XXXXXXX -XX% - X Year XXXXXXXXX +7.10% ### Mentions: XXX [#](/creator/twitter::1408278003109466115/posts_active)  - X Week XXX +93% - X Month XXX +365% - X Months XXX -XX% - X Year XXXXX +53% ### Followers: XXXXX [#](/creator/twitter::1408278003109466115/followers)  - X Week XXXXX +0.54% - X Month XXXXX +2.50% - X Months XXXXX +7.30% - X Year XXXXX +26% ### CreatorRank: XXXXXXX [#](/creator/twitter::1408278003109466115/influencer_rank)  ### Social Influence [#](/creator/twitter::1408278003109466115/influence) --- **Social category influence** [finance](/list/finance) XXXXX% [stocks](/list/stocks) XXXX% [countries](/list/countries) XXXX% [automotive brands](/list/automotive-brands) XXXX% [currencies](/list/currencies) XXXX% [technology brands](/list/technology-brands) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [exchanges](/list/exchanges) XXXX% [celebrities](/list/celebrities) XXXX% **Social topic influence** [$iova](/topic/$iova) #1, [$aqst](/topic/$aqst) #1, [$nklr](/topic/$nklr) #10, [$gsrt](/topic/$gsrt) #4, [$fro](/topic/$fro) #323, [ticker](/topic/ticker) 2.27%, [market cap](/topic/market-cap) #1468, [approved](/topic/approved) #790, [a very](/topic/a-very) 1.52%, [future of](/topic/future-of) XXXX% **Top accounts mentioned or mentioned by** [@therealdansfera](/creator/undefined) [@henry431171040](/creator/undefined) [@cricket99238](/creator/undefined) [@mucosalmelanoma](/creator/undefined) [@abdulla42356398](/creator/undefined) [@america4life72](/creator/undefined) [@trumpokim](/creator/undefined) [@rosenzweigdmd](/creator/undefined) [@bambossie81](/creator/undefined) [@iovancebio](/creator/undefined) [@fdetranay](/creator/undefined) [@jagdish04808041](/creator/undefined) [@the_cheeb](/creator/undefined) [@songkt80](/creator/undefined) [@mhelvz12](/creator/undefined) [@thebrmola](/creator/undefined) [@biospaceinvestr](/creator/undefined) [@sai_hema36144](/creator/undefined) [@fire_truck5](/creator/undefined) [@willmstraya](/creator/undefined) **Top assets mentioned** [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Frontline Ltd. (FRO)](/topic/$fro) [McKesson Corporation (MCK)](/topic/mckesson) [Tesla, Inc. (TSLA)](/topic/tesla) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [AstraZeneca PLC (AZN)](/topic/$azn) [NVIDIA Corp. (NVDA)](/topic/$nvda) [Robinhood Markets, Inc. (HOOD)](/topic/$hood) [Auroracoin (AUR)](/topic/$aur) [Rocket Lab USA, Inc. Common Stock (RKLB)](/topic/$rklb) [Hundred Million (100M)](/topic/$100m) [Oklo Inc. (OKLO)](/topic/$oklo) [NuScale Power Corporation (SMR)](/topic/$smr) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Palantir (PLTR)](/topic/$pltr) ### Top Social Posts [#](/creator/twitter::1408278003109466115/posts) --- Top posts by engagements in the last XX hours "$IOVA - EVP Medical Affairs Brian Gastman MD was asked about interactions with the FDA said the communications have been constant. Our CROChief Regulatory Officer Dr. Raj Puri MD who is an expert on checkpoint inhibitors and cell therapy hired a lot of the people who are making the decisions (at FDA) right now. I believe if the final data for second line NSCLC is positive management is going to push the FDA to give them the new voucher for a X month decision timeline instead of the typical six to XX months. The National Voucher is meant for rare and deadly diseases but the FDA also has the" [X Link](https://x.com/BIOTECHSCANNER/status/1976749041389031785) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T20:37Z 7517 followers, 7797 engagements "$IVF - INVOcell technology is a game changer because its effective and much cheaper than traditional procedures. This will be very attractive to insurers once they are required to cover it. Please watch this video" [X Link](https://x.com/BIOTECHSCANNER/status/1920471561846366380) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-05-08T13:31Z 7514 followers, 4001 engagements "$IOVA - You should report this 🪳 for manipulation. A typical day trader who takes shortcuts instead of doing the hard work like others. X minute they bash next minute they pump. Report this trash. Thanks to the 🐉 for bringing this to my attention" [X Link](https://x.com/BIOTECHSCANNER/status/1967995548411244613) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-16T16:54Z 7515 followers, 5302 engagements "🐉 Family. Its been a while since Ive released a non biotech company. Friday September XX 2025 at 9:30 ET I will release an amazing one. My most recent ones are $NVDA at $XXX before the forward split so $XX split adjusted. $AUR $HOOD and $RKLB are the others. This one will go atomic on us. Full DD coming" [X Link](https://x.com/BIOTECHSCANNER/status/1970906075055653084) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-24T17:40Z 7516 followers, 2583 engagements "The economy is booming with stable inflation and unemployment steady with PCE (personal consumption expenditure) slightly higher in August versus July. What else do you want I actually have not seen this in like a long time. This should keep the Feds continuing with another X quarter point cuts in Q4. Whats that mean Tech sector including biotech will benefit greatly. $IOVA $AQST and the new non-biotech company will flourish in this type of macro economic environment. On top of that Q4 is typically the best performing quarter of the year for the stock market LFG🚀" [X Link](https://x.com/BIOTECHSCANNER/status/1971568392663339018) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-26T13:31Z 7519 followers, 2036 engagements "$AQST $IOVA - Good morning afternoon or evening depending on where you are. Today I will start posting DD on $AQST. Tomorrow will be $IOVA DD release. Monday September XX the name of the non-biotech company and DD will be released at 9:30 am ET and throughout the day. Then on Tuesday September XX 2025 at X pm ET @TheRealDanSfera and I will have a livestream that will go in depth on the X tickers. Have a blessed weekend 🐉 family" [X Link](https://x.com/BIOTECHSCANNER/status/1971974926614630511) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-27T16:27Z 7513 followers, 2981 engagements "$AQST - I released this ticker late February of 2024. Aquestive Therapeutics is a very unique company because its a commercial stage pharmaceutical company that behaves like a clinical stage one. It has been around for XX years but their prodrug products only generate between $40M to $70M per year. They arent still not profitable even after X FDA approvals. Then Dan Barber was promoted to CEO on May XX 2022 and he has been amazing. The main drug the company was counting on to get them out of financial trouble was Libervant for seizure clusters in epilepsy. Libervant was approved BUT only" [X Link](https://x.com/BIOTECHSCANNER/status/1972042506222096673) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-27T20:55Z 7513 followers, 7946 engagements "$AQST - The future of Aquestive depends heavily on their Adrenaverse platform. Adrena refers to Adrenaline or Epinephrine. Verse means multiple or many. The company has figured out how to control the concentration and absorption of epinephrine. This opens the doors to many possibilities in various diseases since epinephrine (adrenaline) is an immune modulator meaning it can influence how the immune system responds to certain conditions. This is powerful. Anaphylm is a great example of immune modulation. After exposure to an allergen the immune system or granulated mast cells release" [X Link](https://x.com/BIOTECHSCANNER/status/1972143212182552823) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-28T03:35Z 7514 followers, 3779 engagements "$AQST - As with all pharmaceutical companies they dont randomly pick a molecule and a disease and saying lets spend $50M to $100M to see if this molecule works on it. Many of them rely on published studies from NIH (National Institutes of Health) or NCI (National Cancer Institute) or other research institutions to see initial evidence that may help them determine whether or not to pursue a particular treatment for a particular disease. A perfect example of this is Dr. Steven A. Rosenberg Chief of Surgery at the National Cancer Institute (NCI) part of the NIH. In the 1980s Dr. Rosenberg and" [X Link](https://x.com/BIOTECHSCANNER/status/1972346510500405386) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-28T17:03Z 7513 followers, 2799 engagements "$GSRT - The market cap of the modular reactor companies like $OKLO and $SMR $NNE will catch up with each other. At the current market cap of $371M $GSRT is a no brainer imo. It will at least 10x from here once more contracts are partnerships come. They will come. Remember the ticker symbol will be changed to $NKLR on Nasdaq after the merger. This will happen sometime after the vote on October X 2025" [X Link](https://x.com/BIOTECHSCANNER/status/1972692474142363803) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-29T15:58Z 7513 followers, 2106 engagements "$GSRT $IOVA $AQST - Tomorrow Tuesday September XX at X pm ET X pm CT and X PT @TheRealDanSfera and I will have a livestream to talk about these companies. I will be sharing some insights that takes too long to post on X. All three have massive catalysts coming soon. I cant wait Hope you can join us" [X Link](https://x.com/BIOTECHSCANNER/status/1972827023715324260) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-30T00:53Z 7514 followers, 3969 engagements "$IOVA - Dr. Anthony Letai sworn in as Director of National Cancer Institute (NCI). Bullish" [X Link](https://x.com/BIOTECHSCANNER/status/1973040872804712738) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-30T15:02Z 7514 followers, 2462 engagements "$AQST $GSRT $IOVA - This is by far my favorite podcast. Chris White the melanoma survivor who received Amtagvi treatment in clinical trial joined us UNEXPECTEDLY Ask yourself this question. The would the person who you followed on X because of their expertise in biotech recall a patient story from their DD or because they release XXX tickers a year and cant remember Choose wisely" [X Link](https://x.com/BIOTECHSCANNER/status/1973181847686234134) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-01T00:23Z 7514 followers, 5281 engagements "$IOVA - Bought the book This is the story of a stage X melanoma survivor who was the LAST patient admitted in the trial for Amtagvi in 2020. He joined our podcast yesterday with @TheRealDanSfera . Dan already bought the book. I already know the story but cant wait to read the book TIL therapy IS THE FUTURE of cancer treatment Why do you think many oncologists incorrectly using Amtagvi as the last line of defense instead of using it sooner Because theres NOTHING else behind Amtagvi. I believe the new mindset coming from key opinion leaders in oncology is recognizing the true benefits of" [X Link](https://x.com/BIOTECHSCANNER/status/1973415796782080075) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-01T15:52Z 7519 followers, 3889 engagements "$AQST $GSRT (NKLR) $IOVA - Have a great weekend 🐉 family. I am so freaking excited for whats coming in the next few months. Each of these X tickers can make explosive moves with positive news especially with $IOVA with X catalysts. I am warning shorts again. Every day we go deeper toward the end of the year are possibilities of PRs dropping X. NSCLC data X. Endometrial cancer data X. IOV-4001 data X. Switzerland marketing approval or application submitted X. Positive Q3 results X. Possible BUYOUT. Cant wait Lastly. I hope none of you lost your $GSRT shares but if you did learn from it" [X Link](https://x.com/BIOTECHSCANNER/status/1974205872323616942) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-03T20:12Z 7514 followers, 3245 engagements "$AQST - One of the dirty sides of Pharma is on full display. NO patient advocacy groups in the allergy community has spoken out against what ARS Pharma did in filing a citizens petition asking the FDA not to approve Anaphylm. Would you guess why This quote is a hint: The root of all evil is the love of MONEY. All of them should close up shop. Lost all respect for them" [X Link](https://x.com/BIOTECHSCANNER/status/1974234111964557677) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-03T22:04Z 7513 followers, 3350 engagements "$AQST $GSRT (NKLR) $IOVA - I love our🐉family and I made the promise since I started this community that I would never turn this into a paid service. NEVER. I dont want to turn family members into customers even though many have recommended to take my DD to other platforms and making it private so I dont take shots from trolls. For every troll there are XX awesome 🐉 members so its not a big deal. The only thing that I have requested from this community is that if you are making profits from my ideas and DD that you would kindly donate a tiny bit of that to . This is the hospital that treats" [X Link](https://x.com/BIOTECHSCANNER/status/1974495325629948171) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-04T15:22Z 7514 followers, 4276 engagements "$IOVA - I have been doing DD all day with new materials that I found and will share with you Monday morning. I am taking a quick break to tell you that NONE OF US HAS ENOUGH SHARES. I truly believe that this ticker is headed towards the teens levels again by the end of this year" [X Link](https://x.com/BIOTECHSCANNER/status/1974629548785283125) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-05T00:15Z 7514 followers, 4822 engagements "$IOVA - To make your weekend even better here is a bonus nugget: Amtagvi or any subsequent drugs approval from $IOVA wont ever go generic because its a living cell therapy. 💥💥💥Enjoy the rest of your weekend" [X Link](https://x.com/BIOTECHSCANNER/status/1974676183230087366) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-05T03:21Z 7516 followers, 4599 engagements "$IOVA - As promised heres the new DD. Much more to come Tesla is the company that supposed to have failed long ago. Today its market cap of more than $1.4T Manufacturing + scaling was a nightmare it almost went bankruptWhy didnt it Elon Musk had VISION. He wanted to change the world by demonstrating how to manufacture EVs at scale and thats EXACTLY what he did He even shared his methods to other companies Tesla did not get to profitability until the mass production of the Model X in 2016. Thats X years after the first electric vehicle rolled off Teslas manufacturing line - the Roadster. In" [X Link](https://x.com/BIOTECHSCANNER/status/1975002149231747225) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T00:56Z 7514 followers, 4863 engagements "$IOVA - Dips are gifts. It will come. Be patient with this one 🐉. It will go nuclear soon. We are in Q4. The last part of the 2H of 2025. The further we get into the end of the year the more condense the timing of the release of data will become. The catalysts will stack up one after another" [X Link](https://x.com/BIOTECHSCANNER/status/1975201827399295026) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T14:09Z 7514 followers, 2301 engagements "$IOVA - I sent this interview with Dr. Brian Gastman MD. If youre interested in investing or already invested you should definitely take a listen. As I have said before $IOVA has gone further than company has ever been before in TIL therapy. The company now has built the infrastructure for TIL manufacturing and continuing to expand. In solid cancers that makes up XX% of all new cancers theres nothing in second line Patients run out of options quickly after checkpoint inhibitors. Not anymore. Amtagvi has demonstrated amazing efficacy that is more than anyone thought possible. $IOVA is saving" [X Link](https://x.com/BIOTECHSCANNER/status/1975218553017000113) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T15:16Z 7514 followers, 2113 engagements "$IOVA - Science refused to let us die young. Its all about the science. TIL therapy is the present and future of cell therapy in solid tumors. Maybe in blood cancers in the future too The company is continuously finding new ways to improve their technology to make TIL treatment more effective. Science" [X Link](https://x.com/BIOTECHSCANNER/status/1975228184716103997) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T15:54Z 7514 followers, 2173 engagements "$IOVA - TIL therapy is the future" [X Link](https://x.com/BIOTECHSCANNER/status/1975239145766195701) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T16:38Z 7514 followers, 2378 engagements "$GSRT $IOVA $AQST - There is one message I post more often than anything else that I put out there. That is PATIENCE I pounded the table on these companies and provided in depth DD. They all will have their own run at some point. I dont know when the run up will come but the only thing I do consistently is to add on dips. If there is a secret recipe to success it is that Be patient and add on dips. Do this only after your conviction is backed by your research" [X Link](https://x.com/BIOTECHSCANNER/status/1975263411316699260) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T18:14Z 7514 followers, 3375 engagements "$IOVA - Immune Checkpoint Inhibitors like these: Anti-PD-1 : Pembrolizumab (Keytruda )nivolumab cemiplimab Anti-PD-L1 : Atezolizumab durvalumab avelumab Anti-CTLA-4 inhibitors: Ipilimumab They are amazing IN FRONTLINE for solid cancers. Unfortunately cancer progression occurs in more than XX% of patients. Besides brutal chemotherapy with X% or less ORR in 2L solid tumors. Theres nothing else. This statistic is also true with metastatic melanoma. Patients ran out of options. Then comes Amtagvi. How did it do in the clinical trial that got its FDA approval in second line metastatic melanoma" [X Link](https://x.com/BIOTECHSCANNER/status/1975284600302936408) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T19:38Z 7514 followers, 2045 engagements "$IOVA - This is such a great conference to listen to. EVERYTHING is in here. CFO Corleen Roche and EVP Medical Affairs Brian Gastman MD talk about revenue restructuring relationship and constant communication with the FDA hiring former FDA experts clinical trials possible trials data release methods and timing pipeline and competitive landscape. Just like $GSRT investors day video I warn you that if you listen to this you will want to get more shares. Guaranteed. Dont listen to it unless you have dry powder 😆" [X Link](https://x.com/BIOTECHSCANNER/status/1975334519591907683) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T22:57Z 7514 followers, 2253 engagements "$IOVA - Iovance Biotherapeutics brought in the big guns with decades of experience at the FDA. Why $IOVA has a massive pipeline with multiple TIL treatments for numerous types of cancers. Think about how his relationships with the FDA will benefit $IOVA and the patients ultimately. This is an amazing hire: Raj K. Puri M.D. Ph.D. Chief Regulatory Officer Dr. Puri joined Iovance in March 2022 as Executive Vice President Regulatory Strategy and Translational Medicine. Dr. Puri was promoted to Chief Regulatory Officer on November XX 2024. He has decades of experience with the evaluation and" [X Link](https://x.com/BIOTECHSCANNER/status/1975362346341085549) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T00:47Z 7514 followers, 2345 engagements "$IOVA - This Cell & Gene meeting in Phoenix AZ on October 6-8 is massive So many big and small biotech companies attending Iovance has two panelist experts on two different general sessions Iovance is getting lots of visibility here. Why not No companies have made it this far in TIL therapy Dan Kirby Chief Operating Officer and Laurel Todd - Head of Policy and Market Access Operations will be the panelists" [X Link](https://x.com/BIOTECHSCANNER/status/1975382810446704997) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T02:08Z 7514 followers, 2279 engagements "$IOVA - Big day at a big Cell & Gene Therapy conference in Phoenix AZ" [X Link](https://x.com/BIOTECHSCANNER/status/1975553571069567006) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T13:27Z 7514 followers, 3458 engagements "$IOVA - Cell & Gene Therapy market to grow exponentially in the next X years. CCO Dan Kirby will be on stage today" [X Link](https://x.com/BIOTECHSCANNER/status/1975559899796152564) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T13:52Z 7514 followers, 4278 engagements "$IOVA - We are currently waiting on updated data on second line 2L Non-Small Cell Lung Cancer (NSCLC) endometrial cancer and IOV-4001 in 2L melanoma. While we are waiting lets take a look at how Amtagvi does in combination with Pembrolizumab (Keytruda) in frontline immune checkpoint inhibitor naive patients shall we As you know NSCLC is deadly. After the patient moves to second line fatality is around 80%. 125K deaths in the US and XXX globally per year. The unmet need is gigantic as you can see. How did Amtagvi do in combination with this amazing drug called Pembrolizumab (Keytruda in" [X Link](https://x.com/BIOTECHSCANNER/status/1975589550454870174) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T15:50Z 7514 followers, 4139 engagements "$IOVA - When positive data (I dont miss) are presented for: X. NSCLC 2L X. Endometrial Cancer 2L X. Next generation TIL (PD-1 Inactivated) in 2L metastatic melanoma Where will you be Are you on the 🚀 or are you admiring it from the afar Everything is right under our noses this whole time. Just look at how Amtagvi is kicking ass in stage X metastatic melanoma. One of the deadliest cancers out there and its getting: Among XX evaluable patients treated at four authorized treatment centers the physician-assessed objective response rate (ORR) was XXXX% (20/41). Response rates with Amtagvi were" [X Link](https://x.com/BIOTECHSCANNER/status/1975693164087329107) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T22:42Z 7518 followers, 4621 engagements "$AQST - XX more years of patent protection Anaphylm will capture at least XX% of the market" [X Link](https://x.com/BIOTECHSCANNER/status/1975910507736612892) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T13:05Z 7514 followers, 2799 engagements "$IOVA - The combination of making large community hospitals and the partnership with InspiroGene by McKesson is a game changer. They are a specialty pharmacy that specializes in complicated treatments and get authorization for the patients X. Oncologists now dont have to send patients to another ATC. They can treat them right at the same hospital. X. Oncologists can start patients on Amtagvi as soon as first line treatments fail them. X. Healthier patients respond much better to Amtagvi treatment thus improving their survival chances. Remember these patients run out of options fast after" [X Link](https://x.com/BIOTECHSCANNER/status/1975931242781552788) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T14:28Z 7514 followers, 2513 engagements "$GSRT - As expected the merger is approved. I am still waiting on when the official ticker change will take place. $NKLR what a name Love this company Will keep you posted" [X Link](https://x.com/BIOTECHSCANNER/status/1975931957445115970) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T14:31Z 7514 followers, 3641 engagements "@mhelvz12 I have done several podcasts with a fellow $IOVA investor @TheRealDanSfera. I cover $IOVA quite a bit on there as well. We did one on Tuesday September XX. We will have a special one on $IOVA pretty soon with Chris White the cancer survivor" [X Link](https://x.com/BIOTECHSCANNER/status/1976108679561621536) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T02:13Z 7514 followers, XXX engagements "@Will_M_Straya Be prepared for 5x that with $IOVA" [X Link](https://x.com/BIOTECHSCANNER/status/1976291176933142698) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T14:18Z 7514 followers, XXX engagements "$AQST - Do you know how many 🪳🪳 called me pumper scammer when I was posting scientifically based DD when the share price dropped to $XXXX at one point this year Did I stop posting No Research based conviction my 🐉🐉🐉. Where are they now" [X Link](https://x.com/BIOTECHSCANNER/status/1976321258829775123) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T16:18Z 7514 followers, 2934 engagements "$IOVA $NKLR $AQST If $NKLR goes nuclear (it will at some point) then $IOVA will go supernova on us. $AQST still could double from here. 🚀🚀🚀" [X Link](https://x.com/BIOTECHSCANNER/status/1976401787545653280) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T21:38Z 7515 followers, 2021 engagements "I have no idea but remember that they have a lot of shares too. Management personnel are shareholders as well. I said the same thing about $AQST. People were worried about dilution. The company will do what is best to move the company forward. That would benefit all of us and the company. They announced the shelf and will tap when needed. All good companies do. ASTS RKLB AQST. The massive catalysts will be definitely present an opportunity. But with a shelf we probably wont know it until they announce during earnings. No worries there for me" [X Link](https://x.com/BIOTECHSCANNER/status/1976429001808769363) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T23:26Z 7514 followers, XXX engagements "$AQST - Dead On Arrival (DOA) will be the final destination of this new option along with Neffy. Belhaven Biopharma will become BelHELL Biopharma. The company is missing the point. Get rid of the device The only way to do that is using the film- Anaphylm The only way to increase the carry curve is to not have a bulky device. This is a bad idea" [X Link](https://x.com/BIOTECHSCANNER/status/1976482401103515740) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T02:58Z 7515 followers, 2555 engagements "$IOVA - Corleen Roche CFO when answering the question of what drew her to Iovance even though she has a long track record at some large companies like Pfizer and Biogen and CG Oncology said I am very excited to be here and tell you all the good things that drew me to Iovance. Number X we cant forget the product is good its on the market and its helping people. Thats the most important thing. I believe the company is in good hands with her. Corleen Roche is very frank and honest. She has launched some big drugs before. Im very impressed by her previous success. Patience 🐉" [X Link](https://x.com/BIOTECHSCANNER/status/1976738115663303080) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T19:54Z 7517 followers, 2628 engagements "@dan_glinert $IOVA - Iovance will have Merck AstraZeneca and BMY drooling soon. The NSCLC market is so big" [X Link](https://x.com/BIOTECHSCANNER/status/1976754014617571419) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T20:57Z 7514 followers, XXX engagements "$NKLR - This will never get old 🤑" [X Link](https://x.com/BIOTECHSCANNER/status/1977827800666292673) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T20:04Z 7516 followers, 4159 engagements "$IOVA $NKLR - If you think $NKLR is explosive just wait until $IOVA releases data coming any day now on NSCLC endometrial cancer and next generation TIL IOV-4001 in second line metastatic melanoma. Current sitting at around $X I believe we may see $10-$12 especially with positive Q3 earnings. I believe theres a XXXX% chance that NSCLC will be positive and the company will use it as part of the accelerated FDA approval. Dont miss this one. I dont miss on data results prediction either" [X Link](https://x.com/BIOTECHSCANNER/status/1977849856216686764) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T21:32Z 7514 followers, 4147 engagements "$IOVA - There is no name that is bigger than McKesson in healthcare services and distribution. It distributes pharmaceuticals medical-surgical supplies and provides healthcare technology solutions. By partnering with InspiroGene by McKesson more patients can get Amtagvi. This is a massive game changer. If there is one thing I know well about the pharmaceutical industry this is it No matter how good the drug is if the insurance approval process is too complicated the prescription will not be filled InspiroGene will leverage Biologics by McKessons more than XX years of specialty pharmacy and" [X Link](https://x.com/BIOTECHSCANNER/status/1978282354767503744) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T02:10Z 7514 followers, 2706 engagements "$IOVA - So apparently I know what I was talking about when I said the partnership with InspiroGene by McKesson is a game changer. XX years of pharmaceutical experience 🐉. Thats what you get from me. Free" [X Link](https://x.com/BIOTECHSCANNER/status/1978465975600087325) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T14:20Z 7515 followers, 2568 engagements "$IOVA - This is a must watch podcast. Thank you @MucosalMelanoma and @TheRealDanSfera for an amazing interview Thanks again to those who watched the podcast" [X Link](https://x.com/BIOTECHSCANNER/status/1978644411102765421) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T02:09Z 7517 followers, 4713 engagements "@PrasaiManish @MucosalMelanoma @TheRealDanSfera Stunning. Once $IOVA gets back to $XX and it will lets get organize a trip there. 😀" [X Link](https://x.com/BIOTECHSCANNER/status/1978691222160994509) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T05:15Z 7517 followers, XXX engagements "I have said it before that diversification in biotech is not a good idea. Find X or two and invest if you have very strong conviction in them. Many times I only have X in my portfolio. My percentage is much higher than XX% for $IOVA. Nothing goes in a straight line. But good companies will eventually rise to the top. People will dwell on the past and thats great for us. We get in at these ridiculously low prices. Good luck to you as well" [X Link](https://x.com/BIOTECHSCANNER/status/1978814659806265620) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T13:25Z 7519 followers, XXX engagements "Its $560K now. Was raised in April. Proleukin is $60-100K depending the patient weight. Key Opinion Leaders (KOLs) are telling everyone to start Amtagvi as soon as frontline treatments failed. Its coming together. Thanks for your contribution to the community by providing good information" [X Link](https://x.com/BIOTECHSCANNER/status/1978879310498021793) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T17:42Z 7514 followers, XX engagements "@Cricket99238 $VKTX was my very first release in December 2023 Released it under $XX and it got to $XXXXX about X months later Thats my specialty. I launched Ozempic with Novo Nordisk" [X Link](https://x.com/BIOTECHSCANNER/status/1979032239187910774) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T03:50Z 7509 followers, XXX engagements "@TrumpoKim I think they have a plan to destroy shorts by the way they are talking. The CFO mentioned the stock price. They are aware that the stock price is suppressed. If the data is good the month doesnt matter. However the longer they wait to cut off data the better the DOR will look" [X Link](https://x.com/BIOTECHSCANNER/status/1979608986098786722) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T18:02Z 7518 followers, XXX engagements "@meputzke20 You can ask me here. Maybe these questions can help the community learn more about $IOVA. This is the standard that I have set. If I dont know the answer I would say so also" [X Link](https://x.com/BIOTECHSCANNER/status/1980003384313688505) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-19T20:09Z 7517 followers, XXX engagements "$IOVA - Just added more for my wifes account. My daughters account has quite a few shares as well now. Any divorce lawyers in 🐉 family 😂. Unbelievably cheap at this price" [X Link](https://x.com/BIOTECHSCANNER/status/1976714622700040350) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T18:21Z 7517 followers, 3195 engagements "$IOVA - Abivax $ABVX with a current market cap at around $7B was trading at $XX on July XX 2025. Then after hours a PR arrived with this headline: Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 Enhancer in Moderate to Severely Active Ulcerative Colitis The next day July XX 2025 it rose to $XXXXX. We are waiting on not X not X but X separate clinical trials data on NSCLC endometrial cancer and melanoma. The total addressable market for just NSCLC alone is already much higher than ulcerative colitis So" [X Link](https://x.com/BIOTECHSCANNER/status/1977911939033358423) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T01:38Z 7517 followers, 5724 engagements "$IOVA - Apparently I called it again. Yesterday I said the company wont release any of the new data that was supposed to be released in 2H of 2025 at the up coming conferences. Here are the two conferences remaining this year. Society for Immunotherapy of Cancer (SITC) 2025 is on November 7-9 in National Harbor Maryland . European Society for Medical Oncology (ESMO) 2025 Congress will be held October 17-21 2025 in Berlin Germany. These are pretty large conferences that will wrap up 2025. The big one ASCO 2026 is not until next year. The biggest oncology conference is The American Society of" [X Link](https://x.com/BIOTECHSCANNER/status/1979589312678162701) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T16:44Z 7517 followers, 4593 engagements "$IOVA - This is EVP Medical Affairs Brian Gastman MD speaking at the Barclays Healthcare Conference back in March of 2025. Unfortunately the recording is no longer available but heres part of what he said about NSCLC data: Hmmm" [X Link](https://x.com/BIOTECHSCANNER/status/1980323739993825630) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T17:22Z 7517 followers, 2316 engagements "$IOVA - Look at how amazing Amtagvi is doing outside of clinical trials and in the real world. Many physicians believe clinical trials are rigged in favor of the drug. But this isnt a clinical trial. These are results compiled from patients who have been treated with Amtagvi and followed them for X years Remember these patients were planning their funerals my friends. Look at what happens to the tumor burden (how much cancer is still in the body). X weeks after Amtagvi treatment and bam Where did it go I have been in the pharmaceutical industry for XX years. I have never seen a company with a" [X Link](https://x.com/BIOTECHSCANNER/status/1978232940116287820) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T22:54Z 7517 followers, 3534 engagements "$IOVA - Buying $IOVA shares now is like buying shares in Tesla when it produces its first EV the Tesla Roadster. Tesla was losing money selling its roadster because manufacturing was expensive. It would have gone bankrupt if it stopped innovating and keeps making only Roadsters on the same assembly lines. Is that what Tesla did Or did it fine tune manufacturing and made numerous other models after the Roadster Tesla did not reach profitability until 2013 with Model S. Consistent profitability did not come until Model X Amtagvi is basically the Roadster for Iovance Except $IOVA can reach" [X Link](https://x.com/BIOTECHSCANNER/status/1978867178725347534) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T16:54Z 7517 followers, 4286 engagements "$IOVA- We dont have enough shares" [X Link](https://x.com/BIOTECHSCANNER/status/1978946187102245078) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T22:08Z 7517 followers, 1911 engagements "$IOVA - By the way I have never missed on data predictions- good or bad. Go back and check. My most recent prediction was someone privately asked me if he should load VKTX before oral VK2735 data. I told him data will be just ok and a big drop will happen BECAUSE THE EXPECTATION WAS TOO HIGH. Not because of the drug. Bam. Exactly as I predicted. He can confirm this if he chooses. I have predicted many positive results before they were released and they all came out as I thought they would. This is not to brag. This is to tell you that hours of research and years of experience help me form my" [X Link](https://x.com/BIOTECHSCANNER/status/1979025266812031304) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T03:22Z 7517 followers, 4357 engagements "@FdetranaY It will be fun brother. People forget how bad they felt when $AQST was below $X just a year ago. $IOVA will be in double digits soon" [X Link](https://x.com/BIOTECHSCANNER/status/1979248963728314644) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T18:11Z 7517 followers, XXX engagements "@Henry431171040 Is this pain similar to when $AQST was under $X Patience my friend. Soon" [X Link](https://x.com/BIOTECHSCANNER/status/1979249440826212387) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T18:13Z 7517 followers, XXX engagements "Have a great weekend 🐉 family. I hope you will spend lots of quality time with your loved ones and cherish every moment Life is very precious yet extremely fragile. Investing in $IOVA and $AQST makes me appreciate life even more. Get rejuvenated and get ready for another exciting week on Monday To those who have invested in $IOVA I know what you have been thinking . Stop it. 😂" [X Link](https://x.com/BIOTECHSCANNER/status/1979312544704561487) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T22:24Z 7517 followers, 2512 engagements "$IOVA - What is the future of TIL The treatment is complicated toxic and expensive. Listen to this podcast and you can hear and learn from Dr. Kelly Mahuron from City of Hope. Notice how Iovance rolls off her tongue like a household name as predicted byme😂. Toward the end of the podcast a question was raised about the future of TIL. Why TIL Because nothing is better right now. People still think of TIL as a static platform for cell therapy. Its the opposite The TIL space is very dynamic What How Did you know that Iovance is working on the next generation TIL and next generation IL-2 and even" [X Link](https://x.com/BIOTECHSCANNER/status/1979671956430733791) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T22:12Z 7517 followers, 2678 engagements "$IOVA - Before I release more DD I just wanted to say: We dont have enough shares of this bottomed out stock🐉fam" [X Link](https://x.com/BIOTECHSCANNER/status/1979974849716957400) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-19T18:16Z 7517 followers, 3719 engagements "With the current FDA explicitly taking a Made in USA stance based on national security concerns be careful investing in companies that conduct clinical trials in China. The FDA will make companies redo trials in the US or at least Europe. I wholeheartedly agree with Dr. Makary and Dr. Prasad on this point. You have no idea the depth of corruption in these countries. Its REALLY BAD. #SMMT" [X Link](https://x.com/BIOTECHSCANNER/status/1979998651788505373) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-19T19:50Z 7517 followers, 2647 engagements "$IOVA - Patience 🤑🤑🤑. This is the #1 biotech from now until the rest of the year. Looking further 2026 will be incredible as the company anticipates multiple exUS approvals supplemental application (sNDA) for Amtagvi in second line NSCLC IND applications (Investigational New Drug) for IOV-5001 next generation TIL for multiple types of solid cancers and second line NSCLC with next generation TIL IOV-4001 as well as next generation IL-2. We should also be getting interim data on frontline metastatic melanoma and NSCLC in the second half of 2026. This is the one 🐉🐉🐉. This is the one. But" [X Link](https://x.com/BIOTECHSCANNER/status/1980055925810475372) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-19T23:38Z 7517 followers, 3445 engagements "@Henry431171040 @TrumpoKim @FdetranaY It wont make that far before Merck Bristol Myers or AstraZeneca bought it. $10B is the price that I believe $IOVA will be sold. But it has to show progress with sales and margins before it gets a buyer. It will be a much better company soon" [X Link](https://x.com/BIOTECHSCANNER/status/1980097461315412223) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T02:23Z 7517 followers, XXX engagements "@FdetranaY @n_hatami @OldGoldHawkeye @Henry431171040 @TrumpoKim Most biotech investors would dream of a NSCLC data as a big catalyst. $IOVA has X additional ones (endometrial cancer and metastatic melanoma). Very exciting times ahead indeed" [X Link](https://x.com/BIOTECHSCANNER/status/1980354826895798703) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T19:25Z 7517 followers, XXX engagements "$IOVA - EU approval is imminent. NSCLC data with a massive addressable market of $66BN is expected in 2H. Shorts are playing with fire and will be smoked. Amtagvi one time treatment has consistently shown tremendous success in wiping out tumors in even hardest to treat population. Easy 10x potential here with patience. We are at the very bottom. Trading almost at cash value. No brainer for me" [X Link](https://x.com/BIOTECHSCANNER/status/1929905562600272340) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-06-03T14:18Z 7518 followers, 2221 engagements "$IOVA - This is Toni English and her testimony on her cancer journey. In 2015 she was diagnosed with Stage X Sinonasal Mucosal Melanoma a very rare and aggressive subtype of melanoma and given X months to live. One year later routine scans showed metastases to my brain both lungs and a kidney. After receiving Amtagvi in clinical trial like Chris White Tonis scans show No Evidence of Disease (NED). But the biggest question I have is what happened to the cancers that spread to the brain lungs and liver How do you think NSCLC data will look I think its going to be amazing Patience" [X Link](https://x.com/BIOTECHSCANNER/status/1975294978302574651) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T20:19Z 7518 followers, 3008 engagements "$IOVA - Did anyone catch what Tonis oncologists told her Here: I was offered a clinical trial that could potentially kill all of my cancer. ALL Then what happened Toni after X months my cancer was gone My scans continue to show NED( No Evidence of Disease). Her oncologists knew about TIL therapy years before Amtagvi was approved. This is why I dont go to doctors who are not up to date on the latest technologies. Her doctors saved her life with the help of Amtagvi. What I am also so impressed about was her oncologists recognizing the potential of Amtagvi to KILL ALL OF HER CANCER (Melanoma" [X Link](https://x.com/BIOTECHSCANNER/status/1975320323550478639) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-06T22:00Z 7518 followers, 2557 engagements "$IOVA - X of these days pre-market or after market PR will announce a buyout from X of the X BPs" [X Link](https://x.com/BIOTECHSCANNER/status/1975402601152655551) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-07T03:27Z 7517 followers, 5107 engagements "$IOVA - Laurel Todd Head of Policy and Market Access is speaking today at the Cell &Gene Meeting On The Mesa. She is probably the third most important person in the company. Market Access is EVERYTHING when launching a product. Dan Kirby Chief Commercial Officer CCO spoke yesterday at this huge conference in Phoenix AZ" [X Link](https://x.com/BIOTECHSCANNER/status/1975908476107833540) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T12:57Z 7517 followers, 3926 engagements "$IOVA - Iovance Biotherapeutics knows that Amtagvi is just the beginning of TIL therapy. The company doesnt sit around and watch Amtagvi kicking stage X metastatic melanoma in the ass. It is constantly trying to improve its products to fight cancer. Why Because cancers dont sit around either It gets stronger. It mutates to hide and deceive the immune system. Iovance Biotherapeutics chose to fight solid tumors while big pharma wants to make money by pouring money into CAR-T because its easier than TIL. Guess which treatment is better for fighting cancer CAR-T is only ok with blood cancers that" [X Link](https://x.com/BIOTECHSCANNER/status/1975935621068624218) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T14:45Z 7517 followers, 2953 engagements "$IOVA - Do not watch this unless you have dry powder to get more shares. Pay attention to the addressable markets in frontline and second lines of Melanoma NSCLC and endometrial cancer. You all have had a chance to load under $X. This is the most exciting biotech company for the next X years at least. It will be in the teens" [X Link](https://x.com/BIOTECHSCANNER/status/1976012742755602773) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T19:52Z 7517 followers, 2899 engagements "$IOVA - There are approximately 8K patients for second line metastatic melanoma in the US. Remember theres nothing else besides chemotherapy in second line. If Amtagvi gets XXX% of the market share thats $XXX billion. But they wont get the entire market. At XX% that is about $X billion. At XX% $X billion. Now add about $80k of IL-2 in there as well. Again Amtagvi has a monopoly in 2L metastatic melanoma This is why I said the company will be more than profitable with just Amtagvi in 2L in the US market alone. The company is also conducting TILVANCE XXX to serve X purposes. X as a confirmatory" [X Link](https://x.com/BIOTECHSCANNER/status/1976048421661270465) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T22:13Z 7517 followers, 2945 engagements "$IOVA $AQST $GSRT ($NKLR) This is my pinned message when you look at my profile. For biotech $IOVA and $AQST they check many of the boxes. $GSRT even though its not a biotech it also checks many boxes too Here it is: How to identify great biotech companies X. Undervalued (low market cap vs assets and market potential) X. Solid management (biotech experience CEO track record and reputation not too many turnovers) X. Great pipeline versus whats currently available (look for first and only or best in class potential. X. Solving a big unmet need X. Incremental successes through various stages of" [X Link](https://x.com/BIOTECHSCANNER/status/1976078711297306919) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T00:14Z 7517 followers, 2624 engagements "$IOVA - Chris White who wrote Killing Cancer with TILs will be on stage to share his testimony on how Amtagvi saved his life from the brink of death at the GLOBAL CANCER RESEARCH AND INNOVATION SYMPOSIUM on October 21st in NYC on behalf of Alliance for Cancer Gene Therapy. Guess what message hes going to share Hes going to say why did his team of oncologists waited SO LONG to recommend him to the clinical trial in 2020. Hes encouraging physicians to recommend Amtagvi SOONER AND HE IS NOT GETTING PAID BY $IOVA. How powerful is that It has to be about the drug as the starting point to invest in" [X Link](https://x.com/BIOTECHSCANNER/status/1976099481977339938) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T01:36Z 7517 followers, 2741 engagements "$IOVA - I just finished reading this book and all I can say is WOW. This book is written without using an editor. You will see numerous spelling grammar and at one point a section was added twice. But Chris White warned the readers at the beginning to expect these errors. Im totally fine with it. Im not going to spoil it for you but I can hint that if this book were a song the most beautiful and powerful part involves the main reason you would invest in $IOVA. I have been in this industry for XX years. I have never witnessed a pharmaceutical company with a treatment platform this good and not" [X Link](https://x.com/BIOTECHSCANNER/status/1976148293064311119) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T04:50Z 7517 followers, 2378 engagements "$IOVA - How do you think these insiders feel about the up coming data releases for NSCLC endometrial cancer and next generation TIL IOV-4001 Hmm" [X Link](https://x.com/BIOTECHSCANNER/status/1976285319931789603) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T13:55Z 7517 followers, 3639 engagements "$IOVA - The company is set to release updated interim data for Amtagvi in second line (2L) NSCLC for patients who have gotten worse on chemotherapy and anti PD-1 before the year ends. July X 2023 was the cutoff date for the previous preliminary data that was released on July XX 2023. This recent data cut included XX NSCLC patients treated with LN-145. An ORR of XXXX% by RECIST v1.1 (n=6 one complete response and five partial responses) was observed with a disease control rate of 82.6%. While still early on study the median duration of response (DOR) was not reached. The DOR ranged from 1.4+" [X Link](https://x.com/BIOTECHSCANNER/status/1976315855874019726) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T15:56Z 7517 followers, 2668 engagements "$IOVA - Big Pharma focuses on the big money. Always Wheres the big money Non-Small Cell Lung Cancer (NSCLC) is where its at. Even in second line the market is massive. Then when you add frontline to the equation big pharma drools. If 2L NSCLC data is positive and I believe it will be $IOVA will become a very hot commodity in biotech. It will further solidify its leadership in TIL therapy. $IOVA has a monopoly in TIL therapy. Look at the addressable market and see it for yourself and also see how Amtagvi demonstrated in preliminary analysis in second line and frontline NSCLC. X pictures" [X Link](https://x.com/BIOTECHSCANNER/status/1976332598335918434) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T17:03Z 7517 followers, 2603 engagements "$AQST $IOVA $GSRT - This is a humbling post and I appreciate the kind words from a 🐉 family member. Its not easy I can tell you especially when several people turned against me JUST BECAUSE THE SHARE PRICE DROPPED. Not anything else. This is what happens when they dont do research and totally put the responsibility on me for their investments. Oh did they missed out on this opportunity and look foolish in the process. Patience is a virtue and so as kindness. Thank you @NLeounakis" [X Link](https://x.com/BIOTECHSCANNER/status/1976345237292212254) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T17:53Z 7517 followers, 2881 engagements "$IOVA - After hiring one of the big guns at the FDA in Dr. Raj Puri who joined Iovance in March 2022 as Executive Vice President Regulatory Strategy and Translational Medicine. Dr. Puri was promoted to Chief Regulatory Officer on November XX 2024. Then on July XX 2025 $IOVA announced another former FDA leader with the appointment of Marc. R Theoret M.D. to assume the newly created position of Senior Vice President Regulatory Strategy where he will focus on clinical regulatory strategy for Iovances pipeline. Effective immediately Dr. Theoret will report to Dr. Raj K. Puri M.D. Ph.D. Chief" [X Link](https://x.com/BIOTECHSCANNER/status/1976357503609995503) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T18:42Z 7517 followers, 3409 engagements "$IOVA - I am having a major case of Deja Vu. Pounding the table when $IOVA is at bottoms and trading at near cash levels like I did with $AQST at $XXXX. As you can see patience 🤑" [X Link](https://x.com/BIOTECHSCANNER/status/1976415484309536860) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T22:32Z 7517 followers, 2758 engagements "$IOVA - Earlier today I posted about the hiring of former FDA leaders Dr. Raj Puri and Dr. Marc Theoret to Iovance Biotherapeutics to focus on Regulatory Strategy.This is a very smart move. Currently they have an amazing working relationship with the FDA. As a matter of fact EVERY TRIAL DESIGNS is done with the FDA and in the case of the Frontline Melanoma and confirmatory trial in 2L melanoma for Amtagvi TILVANCE XXX also with the European Medicines Agency (EMA). This was discussed during the Wells Fargo conference with CFO Corleen Roche and EVP Brian Gastman MD at minute XX. I highly" [X Link](https://x.com/BIOTECHSCANNER/status/1976450785773838647) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T00:52Z 7517 followers, 3075 engagements "@Cricket99238 This is why I tell people if you INVEST you have to stay calm and add on red days. Iovance is 10x better than Orbital Tx. Massive opportunity for investors to invest in $IOVA" [X Link](https://x.com/BIOTECHSCANNER/status/1976686433726251427) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T16:29Z 7517 followers, XXX engagements "$IOVA $AQST - These have nothing to do with tariffs by the way 😀" [X Link](https://x.com/BIOTECHSCANNER/status/1976687125786776056) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T16:31Z 7517 followers, 2625 engagements "$IOVA $AQST $NKLR - All X tickers would have been green yesterday if it werent for a post from the President. I cant stress enough that investing is mostly about mental toughness. There are constantly noises around whether from the macro or micro economic environment or from shorts who live in fear especially if a company has multiple catalysts coming like $IOVA. They have to continually create fear and panic. In these moments we have to lean back to our original thesis on the company that we invested in and asking tough questions like we should. Has anything changed that makes us want to" [X Link](https://x.com/BIOTECHSCANNER/status/1977062003324616958) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-11T17:21Z 7517 followers, 9660 engagements "Yes I have I agree with the fact that it is a long term investment if you want 10x returns in $IOVA. If everything goes well in X years it will be much higher than 5x. Key here is patience. They have something that nobody else has. The TIL market is extremely difficult to get into. Their manufacturing is set. Think about it. XX% of cancers are solid tumors. BP are chasing CAR-T for blood cancers that make up the other 9%. I will take a chance with the bigger market that is 10x bigger. ANY DAY" [X Link](https://x.com/BIOTECHSCANNER/status/1977382752405143785) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T14:36Z 7517 followers, 1013 engagements "$IOVA - Did you know Genesis merged with Lion and later became a dragon (adopted by the 🐉 family) named Iovance. The name reflects its vision to focus on the advancement of immuno-oncology (I/O + advance). Remember the name Lion. Now you know. 😀" [X Link](https://x.com/BIOTECHSCANNER/status/1977388282582356349) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T14:57Z 7517 followers, 2399 engagements "$IOVA $AQST $NKLR - External negative sentiments tend to have a piling on effect. When a stock price drops the bears pile on even more. You should know this by now. This is the main reason I dont go on StockTwits. If you want to be an investor with sound mind dont go on ST. Why do I say this Because even if you dont want to admit or thinking it wont affect you it does. The majority of shorts will go on these platforms to scare you. Thats what they do Their existence depends on the stock price dropping They have a huge incentive to create fear uncertainty and doubt Let me share with you my" [X Link](https://x.com/BIOTECHSCANNER/status/1977417567707771006) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T16:54Z 7517 followers, 3306 engagements "@SantinoD261015 I bought a lot of $IOVA for my wifes account so this may get complicated 🤣" [X Link](https://x.com/BIOTECHSCANNER/status/1977464345761391007) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T20:00Z 7517 followers, XXX engagements "$IOVA - The most important pioneer in tumor-infiltrating lymphocyte (TIL) therapy for cancer. Its come a long way. Thanks to Dr. Steven Rosenberg at the National Cancer Institute (NCI) who came up with the original idea of TIL therapy. The company was founded in 2007 and originally called Genesis Biopharma Inc. in California with the initial focus on developing personalized cell therapies for solid tumors using TIL (tumor-infiltrating lymphocytes) technology. As previously stated the TIL concept came from work at the U.S. National Cancer Institute (NCI) under Dr. Steven Rosenberg a pioneer in" [X Link](https://x.com/BIOTECHSCANNER/status/1977507643079180417) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T22:52Z 7517 followers, 3549 engagements "$IOVA $NKLR $AQST - Guess what Per CNBC Stock futures rebound from Fridays rout after Trump says China situation will all be fine 😂" [X Link](https://x.com/BIOTECHSCANNER/status/1977520920244715967) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-12T23:45Z 7517 followers, 4896 engagements "$IOVA - What if I told you that theres a person who was treated with lifileucel (AMTAGVI) in 2013 when Iovance Biotherapeutics was still called Lion Biotechnologies by the inventor of TIL (Tumor Infiltrating Lymphocytes) therapy Dr. Steven Rosenberg himself; and XX years later hes still a complete responder (CR) with NO EVIDENCE OF DISEASE (NED) This person is Bill Heyman. He recently was interviewed by another complete responder Chris White on TIL TALKS. If you think Chris Whites story is amazing then youre in for another treat. This story has a very moving moment that involves Dr. Steven" [X Link](https://x.com/BIOTECHSCANNER/status/1977557246595715118) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T02:09Z 7517 followers, 6931 engagements "$IOVA - Anne Brooks will be in Philadelphia to participate in Keynote Panel Discussion: State of the Industry Address for Cell and Gene Therapies on November XX. This is what happens when you are the leader in cell therapy. People want to know and learn from you the good and the bad. $IOVA revenue increased XX% from Q1 to Q2. This is the type of progress that we want to see. I expect similar or better growth in Q3 with higher margins. The community hospitals becoming their own ATCs (Authorized Treatment Centers) is a huge deal for several reasons: X. The patients at community hospitals are" [X Link](https://x.com/BIOTECHSCANNER/status/1977748458254598197) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T14:49Z 7517 followers, 2646 engagements "$IOVA $AQST $NKLR You k know what people were saying about $PLTR a couple of years ago when the share price was around $X at the beginning of January 2023 X. They are losing money like crazy X. They are diluting. X. Business not growing X. Business model is too complicated X. What the hell do they do These are the same people who quietly loaded while saying these things. $PLTR is trading at $XXX today. Shorts want you to expect current revenue from $PLTR but should only be paying $X per share. They do this EVERYDAY. They are everywhere. These are the people who tell you that you can enjoy the" [X Link](https://x.com/BIOTECHSCANNER/status/1977762311118229805) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T15:44Z 7517 followers, 3521 engagements "$IOVA - Each day that goes by the timeline is more condensed for these catalysts. There are X sets of data and X events that will be released and occur by year end: X. Non-Small Cell Lung Cancer (NSCLC) - The death rate in the US alone is staggering at 125K per year. Globally its even worse at XXX million per year. No options except chemotherapy and combination with other checkpoint inhibitors that are not effective. The fatality rate is more than XX times higher than melanoma. The patient population is massive. Second line NSCLC indication alone makes $IOVA the envy of the entire cell" [X Link](https://x.com/BIOTECHSCANNER/status/1977801485787259113) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T18:19Z 7517 followers, 2985 engagements "@Cricket99238 Even if I didnt invest in $IOVA I would still wholeheartedly rooting for it to succeed. Who wouldnt Since I am an investor its even easier for me to support its causes 😀. Its going to be fun here soon" [X Link](https://x.com/BIOTECHSCANNER/status/1977841229238071320) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T20:57Z 7517 followers, XXX engagements "@RosenzweigDMD Management is now a strength. CFO Corleen Roche doesnt mess around. She immediately throws the previous CFO under the bus because he misguided into a brand new market. Shes correct. $450M to $475M was too aggressive. $IOVA will be in great shape" [X Link](https://x.com/BIOTECHSCANNER/status/1977874211302523177) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-13T23:08Z 7517 followers, XXX engagements "@biotechreviews Holy moly. Yep I am not surprised. Is there anything better than a new treatment for NSCLC right now Especially when theres none You see why I am saying what I have been saying I am being VERY conservative when I said $10-$12 from current levels for $IOVA. This is biotech" [X Link](https://x.com/BIOTECHSCANNER/status/1977899718182068255) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T00:50Z 7517 followers, XXX engagements "$IOVA - Amtagvi treatment is saving lives and every day the good news is being shared. This ATC (Authorized Treatment Center) has treated over XX patients and is encouraging oncologists to refer patients to them This ATC is in Atlanta Georgia. Thank you @yss4318 for sending this to me. As the saying goes If you build it they will come. $IOVA has an amazing product in Amtagvi. Due to the complicated nature of the treatment the roll out has been slower than anticipated. But the ball is rolling and is picking up momentum. Amtagvi is a tough treatment to receive because cancer is also tough and" [X Link](https://x.com/BIOTECHSCANNER/status/1978104073535492261) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T14:22Z 7516 followers, 4218 engagements "$IOVA - What is The National Comprehensive Cancer Network (NCCN) It is a nonprofit alliance of XX leading U.S. cancer centers including MD Anderson Memorial Sloan Kettering and Dana-Farber that develops widely used clinical practice guidelines for cancer care. NCCNs main work is creating and maintaining evidence-based treatment guidelines for almost every cancer type.These guidelines are used by oncologists insurers and regulatory agencies to decide: X. What the standard of care treatments are. X. When a therapy is appropriate (first line second line etc.) a. How to sequence therapies b. How" [X Link](https://x.com/BIOTECHSCANNER/status/1978129549348012329) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T16:03Z 7516 followers, 2827 engagements "$IOVA - This is the order of PRs that I am hoping we will be getting: X. Q3 earnings💥 X. Switzerland approval💥 X. Endometrial cancer data💥 X. IOV 4001 data for melanoma 💥 X. NCSLC data💥 The company has mentioned that they want to let the data matured because of the exceptional durability of the TIL treatment that will favor Duration of Response (DOR). So maybe we will get X sets of data in December. I am completely cool with that. But if Q3 earnings is positive the stage is set for potentially the biggest runner in biotech this year with X catalysts. If you are waiting on X catalyst its" [X Link](https://x.com/BIOTECHSCANNER/status/1978200131024343316) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T20:43Z 7516 followers, 4402 engagements "$IOVA - Chemotherapy combos in second line NSCLC get about X% ORR. They are pathetic. You want to talk about a low bar and the extremely high unmet need in this population Society desperately needs Amtagvi to get approved ASAP if the ORR is XX% or above and DOR is X months or above. 125K deaths in the US and XXX million deaths globally per year. And its only gotten worse Data from 2023 already showing ORR XXXX% (6/23); DOR XX% of confirmed responders had responses lasting X months. Disease Control Rate (DCR) 82.6%. We are getting data sometime in the next X months. Trust me when I say this:" [X Link](https://x.com/BIOTECHSCANNER/status/1978217384407175528) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-14T21:52Z 7517 followers, 2716 engagements "@SMAC1945 Definitely not. Actually Prasad and Makary make me more bullish on $IOVA. THEY are constantly in communication with the FDA. Many people who are approving cancer drugs right now were hired by Dr. Puri Chief Regulatory Officer at $IOVA" [X Link](https://x.com/BIOTECHSCANNER/status/1978257226763579455) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T00:30Z 7517 followers, XXX engagements "@mhelvz12 Nice I definitely believe so. $IOVA will be bought out way before XX years from now. I think X years max" [X Link](https://x.com/BIOTECHSCANNER/status/1978259165765095446) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T00:38Z 7516 followers, XXX engagements "$IOVA - What does Amtagvi say to tumor burden Where are you now @IovanceBio" [X Link](https://x.com/BIOTECHSCANNER/status/1978287464235045027) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T02:31Z 7517 followers, 3490 engagements "Im going to continue to share your story Chris. On February XX 2024 I tweeted an interview that you did with someone. About XX minutes later the PR from $IOVA announcing approval of Amtagvi. I have been tell people that it doesnt matter if they are investing in Iovance or not they should support the company because someday they or someone they know may need TIL treatment from Iovance. I appreciate you continuing to share your miraculous story. I look forward to seeing you on @TheRealDanSfera podcast hopefully after you get back from NYC" [X Link](https://x.com/BIOTECHSCANNER/status/1978306232701112468) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T03:45Z 7517 followers, XXX engagements "$IOVA - The company plans to release interim data on: X. Second Line NSCLC - If data is positive then they will wait for phase X to end and then apply for accelerated approval. Because this phase X is a pivotal trial. The company is using the same process as second line metastatic melanoma. The frontline NSCLC in combination with Pembrolizumab will have a dual purpose just like TILVANCE XXX that is to serve as a confirmatory for full second line NSCLC and accelerated frontline approval as well. A lot of attention is paid toward this data release because the NSCLC market is more than 6x of" [X Link](https://x.com/BIOTECHSCANNER/status/1978456463392530488) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T13:42Z 7517 followers, 2550 engagements "$IOVA - This is the one. Amtagvi by itself is worth 5x the current price. That is a conservative estimate btw" [X Link](https://x.com/BIOTECHSCANNER/status/1978471176679702958) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T14:41Z 7516 followers, 3577 engagements "@thebrmola Its not even close. Look at the pipeline. $AQST can double from here while $IOVA can XX x from here at minimum because NSCLC would have been approved as well as frontline metastatic melanoma" [X Link](https://x.com/BIOTECHSCANNER/status/1978482378948448587) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T15:25Z 7517 followers, XXX engagements "$IOVA - InspiroGene partnership solves this bottleneck. This is what they do. They have oncologists on staff to talk to insurance companies to get treatment authorized. They are experts in the latest treatment guidelines. InspiroGene lets the healthcare providers treat patients and the patients focusing on getting their health and lives back. Fewer prescriptions drop off means more sales of Amtagvi. 💥" [X Link](https://x.com/BIOTECHSCANNER/status/1978511407529222258) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T17:20Z 7517 followers, 3583 engagements "$IOVA - Lets hear it from the InspiroGene leader Joe DePinto. With a massive pipeline that Iovance has this partnership is a perfect fit. InspiroGene works with the patients and insurers to get them approved for treatment. With many more patients coming in from community hospitals InspiroGene takes care of all of the logistics from treatment approvals to reimbursement for healthcare providers and hospitals" [X Link](https://x.com/BIOTECHSCANNER/status/1978530857351839783) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T18:38Z 7517 followers, 2469 engagements "$IOVA - There are 30000 second line metastatic melanoma patients (8K US+22K exUS) and Amtagvi is the only treatment indicated to treat these patients after chemotherapy radiation ICIs are CTLA-4 failed them. $IOVA only needs to treat XX% of the US patients population in second line metastatic melanoma that is 2000 patients per year and generates over $XXX billion in Amtagvi + Proleukin (IL-2) sales. Now do the math when ex-US approvals arrive. Canada already had approved Amtagvi. Thats just second line metastatic melanoma Now add frontline metastatic melanoma for US and ex-US. We are not" [X Link](https://x.com/BIOTECHSCANNER/status/1978544044671422496) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T19:30Z 7517 followers, 2776 engagements "@peter_paone Dont forget to celebrate small victories on our way to the big one" [X Link](https://x.com/BIOTECHSCANNER/status/1978562937951273150) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T20:45Z 7517 followers, XXX engagements "$IOVA - Dragon fam. @TheRealDanSfera and I have a last minute special podcast for you. On this podcast you will get to meet the mucosal melanoma survivor named Chris White who wrote the book Killing Cancer With TILs. This will be an all out IOVA focused podcast. We will cover everything from the patient perspective to clinical trials and the business case for Iovance. It will be at 7:30 Pm EST 6:30 CT and 4:30 PST. I am beyond pumped Hope you can join" [X Link](https://x.com/BIOTECHSCANNER/status/1978567533063213346) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T21:03Z 7517 followers, 2578 engagements "@BioSpaceInvestr @MucosalMelanoma Nice 10k shares is a great I agree with you. $IOVA will succeed because the treatment is amazing and saves lives" [X Link](https://x.com/BIOTECHSCANNER/status/1978659139808084419) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T03:07Z 7517 followers, XXX engagements "$IOVA - Shorts will want you to focus on the toxicity of the treatment with Amtagvi. But yesterday you heard from the patient Chris White yourself. The toxicity of the previous lines of treatment (chemotherapy radiation checkpoint inhibitors) that he is still dealing with on a daily basis. He said none of the parts of the Amtagvi treatment regimen side effects bother him after the treatment was done. Its the OTHER previous treatments that is STILL HURTING HIM. @MucosalMelanoma can reconfirm with me here. Amtagvi is the MOST EFFECTIVE TREATMENT in second line metastatic melanoma. PERIOD" [X Link](https://x.com/BIOTECHSCANNER/status/1978816419249652109) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T13:32Z 7517 followers, 3073 engagements "@Storm28799 They will not sell $IOVA for less than $X billion. The longer they wait the more they will have to pay if Amtagvi sales increase and new indications coming like NSCLC" [X Link](https://x.com/BIOTECHSCANNER/status/1979194040923877389) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T14:33Z 7517 followers, XXX engagements "Thanks for your kind compliments. Your analysis in this video is fair and honest. This is exactly what we want. The information has to meet the standard of accuracy as much as possible and you did a great job The only thing I want to point out is that $IOVA headquarters is in San Carlos California and the Iovance Cell Therapy Center (iCTC) is in Philadelphia Pennsylvania. This is where T cells are shipped to. Thank you for your contribution to the biotech investment community. Its fun to win; its a blast to win together (Patients+Company+Investors) F shorts" [X Link](https://x.com/BIOTECHSCANNER/status/1979586005129687343) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T16:30Z 7517 followers, XXX engagements "@proudghanaman Yep One of my favorite Mortal Kombat characters" [X Link](https://x.com/BIOTECHSCANNER/status/1979680550844788812) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T22:46Z 7517 followers, XXX engagements "@theRodgerRoundy Very nice Absolute free gifts at these levels. I pounded the table when $AQST was below $X and look where its at. This will go ballistic in the next couple of months" [X Link](https://x.com/BIOTECHSCANNER/status/1978524403609539050) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T18:12Z 7517 followers, XXX engagements "$IOVA - I hope you know I dont randomly make up stuff. I spend a lot of time doing research. I read constantly to keep up with the latest developments in medicine and biotech. Why Has nothing to do with investing. Its my love for science and medicine to be more specific. I have done this way before I started investing. So every thing I posted on any biotech company is done with my research and understanding. Am I right all the time Probably not. But most of the time Based on my track record Hell yes I dont take the responsibility lightly because it involves money. I understand the risks and" [X Link](https://x.com/BIOTECHSCANNER/status/1978963956342337833) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T23:19Z 7518 followers, 2565 engagements "$IOVA - X companies that may acquire Iovance Biotherapeutics. X. $MRK (Merck) X. $BMY (Bristol Myers) X. $AZN (AstraZeneca) These X have extensive oncology portfolios. $AZN recently has been extremely aggressive to get into cell and gene therapy. $MRK and $BMY have checkpoint inhibitors that would go very well with Amtagvi and future TIL products in $IOVAs pipeline" [X Link](https://x.com/BIOTECHSCANNER/status/1972526798186377473) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-29T05:00Z 7518 followers, 8611 engagements "$GSRT - By the way this is now my biggest position in the portfolio. Even bigger than $IOVA and I have a lot there. $AQST is in third place. This is the new three headed monster. To a bright future 🚀. Patience 🤑. I cant wait to see $NKLR on the list. Love the ticker symbol" [X Link](https://x.com/BIOTECHSCANNER/status/1972766846526111919) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-09-29T20:54Z 7518 followers, 3755 engagements "$IOVA - Warning to shorts. Your days are numbered1.NSCLC data X. Endometrial cancer data X. Next Generation TIL IOV-4001 data in 2L melanoma X. Possible approval marketing authorization for Amtagvi in Switzerland or approval application submission X. Solid Q3 earnings" [X Link](https://x.com/BIOTECHSCANNER/status/1976280281523912726) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T13:35Z 7518 followers, 2688 engagements "@Cricket99238 $IOVA will be at least a $20Bn company. It will actually be bought out before 2026 is over by Merck Bristol Myers or AstraZeneca" [X Link](https://x.com/BIOTECHSCANNER/status/1976420083724583048) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-09T22:50Z 7518 followers, XXX engagements "$IOVA - Cell & Gene Therapy is the hottest sector within biotech. Today Bristol Myers Squibb acquired Orbital Therapeutics that has CAR-T assets for autoimmune diseases. I have said it many times I believe Iovance will be acquired at some point by big pharma. Especially if the NSCLC data is positive in second line. I believe the data will be very positive. In frontline NSCLC using Amtagvi and Pembrolizumab (Keytruda) its already shown incredible efficacy and durability. Patience" [X Link](https://x.com/BIOTECHSCANNER/status/1976655405641015375) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-10T14:25Z 7518 followers, 3229 engagements "$IOVA - Last week I said this (post attached below). Today the FDA did exactly what I had predicted. They widened the definition including non-rare diseases. The FDA announced the first group that may qualify for the new National Priority Review Voucher Program. One drug that the FDA intends to grant the voucher to is for pancreatic cancer due to the large unmet need. This is amazing news for $IOVA. Why In 2025 there are approximately 52K pancreatic cancer deaths in the US. In NSCLC there are 125K deaths per year in the US This is why I said that if data for NSCLC is positive $IOVA will apply" [X Link](https://x.com/BIOTECHSCANNER/status/1978987835211313542) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T00:54Z 7517 followers, 4251 engagements "Thank you my friend I really appreciate you donating to St. Jude. Im actually going to do something extra for them if $IOVA and $AQST turn out well. $AQST is almost there and $IOVA will actually surpass it soon. I love these X. $NKLR has become a meme like ticker. I will let it chill for a bit" [X Link](https://x.com/BIOTECHSCANNER/status/1979050763079778794) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T05:04Z 7518 followers, XXX engagements "Treatment price is not prohibitive. If the patient has insurance it will be covered if Amtagvi is on that particular plan. Did you hear that after they increased the price from $515K to $560K sales increased I have done this a long time. These treatments are for insurance only. No one can afford paying cash. The company knows this. If the patient needs treatment there is a patient assistance program. Management addressed margin improvements and it is related to the community hospitals becoming ATCs. Healthier patients come from these hospitals. Healthier patients improve TIL quality thus" [X Link](https://x.com/BIOTECHSCANNER/status/1980321109099868188) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T17:11Z 7518 followers, XX engagements "$IOVA - What makes Amtagvi unique Why can it destroy cancer cells in solid tumors that CAR-T cant Because the T-cells in Amtagvi are REACTIVE T-cells. Whats that mean TIL (Tumor Infiltrating Lymphocytes) are harvested from at least a 1.5cm of tumor tissue. These lymphocytes already infiltrated or entered the tumor and fighting in the tumor micro environment. These lymphocytes already REACTED or RECOGNIZED the cancer cells whereas in CAR-T the T lymphocytes are collected from the peripheral blood. These T-cells could have been watching Monday Night Football when they were gathered then" [X Link](https://x.com/BIOTECHSCANNER/status/1975973162354385399) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-08T17:14Z 7517 followers, 3127 engagements "$IOVA - Did you know in 2nd Line Metastatic Melanoma Non-Small Cell Lung Cancer (NSCLC) and Endometrial Cancer THERE IS NO EFFECTIVE TREATMENT and patients only have months to live Immune Checkpoint Inhibitors like Keytruda (pembrolizumab) an anti-PD-1 and Yervoy (ipilimumab) a CTLA-4 were initially indicated for second line after chemotherapy and radiation but since had been moved into frontline. Still XX% or more see their cancers progressed or got worse. Now theres only chemo and other drugs combined to help but they are not effective. Then comes badass Amtagvi. In the pivotal phase 2" [X Link](https://x.com/BIOTECHSCANNER/status/1976846047226859870) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-11T03:03Z 7517 followers, 4004 engagements "$IOVA - I posted this earlier but it deserves to be mentioned again. In a $370B market of cellular therapy where Iovance Biotherapeutics has a monopoly in TIL. First with melanoma then potentially NSCLC and endometrial cancer. After that next generation TIL like IOV - 4001 PD-1 inactivated and IOV- 5001 IL-12 tethered TIL will open doors to other solid cancers like breast and head and neck. Next generation IL-2 if still needed is also in clinical trial as well. And youre worried about pennies We dont have enough shares of this company 🐉" [X Link](https://x.com/BIOTECHSCANNER/status/1978484806938669530) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T15:35Z 7517 followers, 2462 engagements "$IOVA $AQST -" [X Link](https://x.com/BIOTECHSCANNER/status/1978560539094569044) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T20:36Z 7517 followers, 2858 engagements "$IOVA - I will be using this checklist for $IOVA during the podcast today. This is pinned on my profile. There are quite a few potential investors in $IOVA so I have to kind of going back over the fundamentals. X. Undervalued (low market cap vs assets and market potential)✅ X. Solid management (biotech experience CEO track record and reputation not too many turnovers)✅ X. Great pipeline versus whats currently available (look for first and only or best in class potential.✅ X. Solving a big unmet need ✅ X. Incremental successes through various stages of clinical trials ✅ X. Strong upcoming" [X Link](https://x.com/BIOTECHSCANNER/status/1978594899252420859) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-15T22:52Z 7517 followers, 2909 engagements "$IOVA - This is X of the latest innovative potential treatment in second line melanoma using mRNA-4359 in combination with Keytruda. This was posted by Targeted Oncology X hours ago. This treatment involves multiple injections Results: ORR: XX% WITH KEYTRUDA In a PD-1 positive population which is an easier to treat than PD-1/PD-L1 negative population. Amtagvi by itself in phase X : ORR XXXX% mDOR XXXX months with twice the number of patients with PD-L1 negative of XX% and PD-1 positive 33%. Again PD-1/PD-L1 negative is harder to treat. Then a X year real world retrospective physician assessed" [X Link](https://x.com/BIOTECHSCANNER/status/1978932946179383385) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T21:15Z 7517 followers, 3504 engagements "$IVF - I thought I probably had to take a loss for tax purposes but now will get more $IOVA. Patience 🤑always wins" [X Link](https://x.com/BIOTECHSCANNER/status/1978934086862286963) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-16T21:20Z 7517 followers, 2406 engagements "$IOVA - If interim phase X data for NSCLC being released anytime in Q4 is positive I believe theres almost a XXX% chance that Amtagvi will get the National Priority Review Voucher cutting FDA decision from 6-10 months to 1-2 months after the final data arrives several months later. The innovation of TIL therapys X time treatment and a massive unmet need in second line NSCLC makes perfect sense for the FDA to grant Amtagvi the priority voucher. After this frontline metastic melanoma in combination with Pembrolizumab in TILVANCE XXX is on deck. Then frontline NSCLC in combination with" [X Link](https://x.com/BIOTECHSCANNER/status/1979019381179924647) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T02:59Z 7517 followers, 2342 engagements "$IOVA - What is Amtagvi(lifileucel) It is the first ever TIL cell therapy treatment indicated for second line metastatic melanoma. These patients after first line treatments failed have no options besides more ineffective and punishing chemotherapy in combination with other drugs that already been used AND FAILED like Keytruda and Yervoy from the powerful class of drugs called checkpoint inhibitor. Then comes Amtagvi. In clinical trials it showed Objective Response Rate (ORR) XXXX% and median Duration of Response (mDOR)36.5 months. Remember these patients only have months and are more often" [X Link](https://x.com/BIOTECHSCANNER/status/1979183828863189410) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T13:52Z 7517 followers, 2235 engagements "$IOVA - We all have the opportunity to load at this bottomed out level. With the up coming catalysts shorts that piled in are at the mercy of the company as to when and how they will release the PRs. The company already said they will publish data in a peer review journal for maximum credibility and exposure. It is more time consuming and expensive but wanted to have stricter standards and more respect to the data. After that they will release via PR. No dates have been set. PRs may be released on any given day between today and the end of the year. Theres not many trading weeks left All of" [X Link](https://x.com/BIOTECHSCANNER/status/1979224166273552573) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T16:33Z 7517 followers, 2275 engagements "$IOVA - When theres no hope left for patientsTheres Amtagvi @IovanceBio @MucosalMelanoma" [X Link](https://x.com/BIOTECHSCANNER/status/1979258805499170950) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T18:50Z 7517 followers, 1750 engagements "$IOVA - @Merck Your Iovance Biotherapeutics and you can team up to defeat solid cancers like in the Frontline metastatic melanoma study TILVANCE XXX right now. You dont have to look very far. If not AstraZeneca will. @IovanceBio" [X Link](https://x.com/BIOTECHSCANNER/status/1979281186825335067) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T20:19Z 7517 followers, 1078 engagements "$IOVA - You may notice that the company probably will not release ANY clinical trials data at upcoming conferences. This is EXACTLY what we want. Iovance wants to publish data in a peer reviewed journal. It is more expensive and time consuming BUT if they want to destroy shorts this is how to do it. Publish data in peer reviewed journal and send it via PRs through numerous news outlets. Dr. Brian Gastman EVP Medical Affairs talked about how the company is going to be releasing data during the Wells Fargo Healthcare Conference on September X 2025. After releasing data via PRs the company will" [X Link](https://x.com/BIOTECHSCANNER/status/1979290785821417867) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T20:57Z 7517 followers, 2505 engagements "$IOVA - My notifications just bing and I thought a PR was released 😆. It for inducement grants. Which is bullish by the way. X new employees" [X Link](https://x.com/BIOTECHSCANNER/status/1979296501437448335) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-17T21:20Z 7517 followers, 2212 engagements "$IOVA - ATTENTION 🐉🐉🐉😀. Data for NSCLC endometrial cancer and IOVA 4001 in second line metastatic melanoma will be released via Press Releases (PRs) as stated by Dr. Brian Gastman EVP Medical Affairs. Data will be released by end of year. Hes in charge of all things related to clinical trials at Iovance Biotherapeutics. He wants data to be published in a prestigious scientific journal that is peer reviewed. This is exactly what every company wants if they have ground breaking or breakthrough data in areas with large unmet needs. Non-Small Cells Lung Cancer (NSCLC) endometrial cancer and" [X Link](https://x.com/BIOTECHSCANNER/status/1979602103107809723) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T17:34Z 7517 followers, 2584 engagements "$IOVA - Its such perfect timing when @IovanceBio released the poster that will be presented at European Society for Medical Oncology Congress 2025 one of the largest and most influential annual oncology meetings in the world similar in importance to ASCO and SITC. The poster titled Evaluating curative potential of lifileucel in previously treated advanced melanoma: Analyses from C-144-01 Trial Think about this: For patients who progressed from frontline to second line metastatic melanoma after previous treatments like chemotherapy and immune checkpoint inhibitors have failed them. These" [X Link](https://x.com/BIOTECHSCANNER/status/1979649851139727813) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T20:44Z 7517 followers, 1850 engagements "$IOVA - This isnt competition on efficacy. Its competition for attention. Amtagvi will win on both fronts. The world is beginning to recognize the power of a X time treatment with unsurpassed efficacy and durability. Conviction through science backed research. I got you covered. Its good that we talk about it" [X Link](https://x.com/BIOTECHSCANNER/status/1979665726450581554) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-18T21:47Z 7517 followers, 4163 engagements "$IOVA - When I decided to use my biology background and pharmaceutical experience to find biotech and tech companies to invest in I began with a checklist. Its pinned to my profile. The current one was updated a year and X months ago. I may tweak it again but it still looks exactly as I wanted it. I am going to use the checklist on $IOVA and fill in the details as to why it gets a check mark on each item. How to identify great biotech companies: $IOVA X. Undervalued (low market cap vs assets and market potential)✅ The current share price (SP) is $XXXX market cap (MC)is at $788M. The MC is" [X Link](https://x.com/BIOTECHSCANNER/status/1980095391296356354) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T02:15Z 7517 followers, 2954 engagements "$IOVA - Other potential treatments can only dream. Nothing is better than Amtagvi X time treatment. This is X year REAL WORLD EVIDENCE that the new FDA loves" [X Link](https://x.com/BIOTECHSCANNER/status/1980265084560568450) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T13:29Z 7517 followers, 2517 engagements "$IOVA - I saw REPL got their BLA resubmission accepted by the FDA. They received a CRL in July. A new PDUFA date is set for April XX 2026. I am not sure if they have addressed all of the concerns from the FDA in this application. Approval is 50/50 at best. REPL received a CRL because: X. The supporting Phase 1/2 IGNYTE trial was not an adequate and well-controlled clinical investigation per the FDAs determination. 2.The patient population in IGNYTE was too heterogeneous which limited interpretability of the data. 3.The ongoing confirmatory trial (IGNYTE-3) had design issues especially around" [X Link](https://x.com/BIOTECHSCANNER/status/1980268147799118153) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T13:41Z 7517 followers, 1969 engagements "$IOVA - The company continues to invest in its business and future. It could easily become profitable with Amtagvi alone. It is investing massively in its future business with XX clinical trials in solid cancers and blood cancers as well as well as new generation TIL and IL-2. The concerns of the large R&D expenses will be squashed soon with new data on NSCLC that will be used to apply for the newly created National Priority Voucher. This qualifies Amtagvi for a 1-2 month review for accelerated approval. There is more than 10000 patients died of NSCLC per month in the US. You think this is" [X Link](https://x.com/BIOTECHSCANNER/status/1980271759623418226) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T13:55Z 7517 followers, 2217 engagements "$IOVA - Checklist #2 X. Solid management (biotech experience CEO track record and reputation not too many turnovers)✅ After the slower than forecasted Amtagvi launch management made some big changes. X. New Chief Commercial Officer- Dan Kirby. Immediately after arriving at Iovance implements key initiatives to drive early Amtagvi adoption that will help speed up sales tremendously over time. Namely the inclusion of community hospitals as their own authorized treatment centers (ATCs) and partnership with InspiroGene by McKesson. InspiroGene to provide services such logistics for treatment" [X Link](https://x.com/BIOTECHSCANNER/status/1980293767434322113) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T15:23Z 7517 followers, 1874 engagements "$IOVA - Im telling you right now the new NSCLC data will be transformative for the patients and the company. With the massive unmet need in this deadly cancer Amtagvi will qualify for the new priority review voucher. The review timeframe will be 1-2 months after the sBLA is accepted. Need further evidence The FDA is going to cut down the approval timeline for all drugs in the future as well This is amazing for biotech and patients" [X Link](https://x.com/BIOTECHSCANNER/status/1980299206687428936) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T15:44Z 7517 followers, 3791 engagements "$IOVA $AQST - Tomorrow at X pm ET X pm CST and 3pm PST" [X Link](https://x.com/BIOTECHSCANNER/status/1980304629046170011) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T16:06Z 7517 followers, 2996 engagements "@n_hatami I would take shares as payments Thank you brother" [X Link](https://x.com/BIOTECHSCANNER/status/1980321879295668361) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T17:15Z 7518 followers, XX engagements "$IOVA - Checklist #3 How to identify great biotech companies. X. Great pipeline versus whats currently available (look for first and only or best in class potential.✅ This is probably the easiest one Amtagvi is the ONLY treatment specifically indicated to treat second line metastatic melanoma. THERES NOTHING ELSE except more ineffective chemotherapy in combination with other immunotherapy that cancer already beat. In the phase X trial where Amtagvi received accelerated approval on February 162024 the results were impressive. ORR XXXX% mDOR XXXX months. Then the company recently released a 5" [X Link](https://x.com/BIOTECHSCANNER/status/1980362859935649923) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T19:57Z 7517 followers, 2047 engagements "$IOVA - You think Iovance Therapeutics may be a hot commodity after positive data being released by the end of this year Here are the data we are waiting on: X. 2L Non-Small Cell Lung Cancer (NSCLC). X. 2L Endometrial Cancer X. 2L metastatic melanoma using next generation TIL IOV 4001 (genetically engineered PD-1 inactivated). This is like Amtagvi with Keytruda 💥. Look who just threw in the towel trying to develop advanced melanoma vaccine" [X Link](https://x.com/BIOTECHSCANNER/status/1980398919822807078) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-20T22:21Z 7517 followers, 2302 engagements "@RosenzweigDMD X. Merck X. BMY X. AstraZeneca" [X Link](https://x.com/BIOTECHSCANNER/status/1980441914160885965) [@BIOTECHSCANNER](/creator/x/BIOTECHSCANNER) 2025-10-21T01:12Z 7517 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BIOTECHSCANNER BIOTECH SCANNER
BIOTECH SCANNER posts on X about $iova, $aqst, $nklr, $gsrt the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXX -XX%
- X Month XXXXXXX +273%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +7.10%
Mentions: XXX #
- X Week XXX +93%
- X Month XXX +365%
- X Months XXX -XX%
- X Year XXXXX +53%
Followers: XXXXX #
- X Week XXXXX +0.54%
- X Month XXXXX +2.50%
- X Months XXXXX +7.30%
- X Year XXXXX +26%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence finance XXXXX% stocks XXXX% countries XXXX% automotive brands XXXX% currencies XXXX% technology brands XXXX% cryptocurrencies XXXX% exchanges XXXX% celebrities XXXX%
Social topic influence $iova #1, $aqst #1, $nklr #10, $gsrt #4, $fro #323, ticker 2.27%, market cap #1468, approved #790, a very 1.52%, future of XXXX%
Top accounts mentioned or mentioned by @therealdansfera @henry431171040 @cricket99238 @mucosalmelanoma @abdulla42356398 @america4life72 @trumpokim @rosenzweigdmd @bambossie81 @iovancebio @fdetranay @jagdish04808041 @the_cheeb @songkt80 @mhelvz12 @thebrmola @biospaceinvestr @sai_hema36144 @fire_truck5 @willmstraya
Top assets mentioned Iovance Biotherapeutics, Inc. Common Stock (IOVA) Frontline Ltd. (FRO) McKesson Corporation (MCK) Tesla, Inc. (TSLA) Merck & Co., Inc. (MRK) Bristol-Myers Squibb Co (BMY) AstraZeneca PLC (AZN) NVIDIA Corp. (NVDA) Robinhood Markets, Inc. (HOOD) Auroracoin (AUR) Rocket Lab USA, Inc. Common Stock (RKLB) Hundred Million (100M) Oklo Inc. (OKLO) NuScale Power Corporation (SMR) Viking Therapeutics, Inc (VKTX) Palantir (PLTR)
Top Social Posts #
Top posts by engagements in the last XX hours
"$IOVA - EVP Medical Affairs Brian Gastman MD was asked about interactions with the FDA said the communications have been constant. Our CROChief Regulatory Officer Dr. Raj Puri MD who is an expert on checkpoint inhibitors and cell therapy hired a lot of the people who are making the decisions (at FDA) right now. I believe if the final data for second line NSCLC is positive management is going to push the FDA to give them the new voucher for a X month decision timeline instead of the typical six to XX months. The National Voucher is meant for rare and deadly diseases but the FDA also has the"
X Link @BIOTECHSCANNER 2025-10-10T20:37Z 7517 followers, 7797 engagements
"$IVF - INVOcell technology is a game changer because its effective and much cheaper than traditional procedures. This will be very attractive to insurers once they are required to cover it. Please watch this video"
X Link @BIOTECHSCANNER 2025-05-08T13:31Z 7514 followers, 4001 engagements
"$IOVA - You should report this 🪳 for manipulation. A typical day trader who takes shortcuts instead of doing the hard work like others. X minute they bash next minute they pump. Report this trash. Thanks to the 🐉 for bringing this to my attention"
X Link @BIOTECHSCANNER 2025-09-16T16:54Z 7515 followers, 5302 engagements
"🐉 Family. Its been a while since Ive released a non biotech company. Friday September XX 2025 at 9:30 ET I will release an amazing one. My most recent ones are $NVDA at $XXX before the forward split so $XX split adjusted. $AUR $HOOD and $RKLB are the others. This one will go atomic on us. Full DD coming"
X Link @BIOTECHSCANNER 2025-09-24T17:40Z 7516 followers, 2583 engagements
"The economy is booming with stable inflation and unemployment steady with PCE (personal consumption expenditure) slightly higher in August versus July. What else do you want I actually have not seen this in like a long time. This should keep the Feds continuing with another X quarter point cuts in Q4. Whats that mean Tech sector including biotech will benefit greatly. $IOVA $AQST and the new non-biotech company will flourish in this type of macro economic environment. On top of that Q4 is typically the best performing quarter of the year for the stock market LFG🚀"
X Link @BIOTECHSCANNER 2025-09-26T13:31Z 7519 followers, 2036 engagements
"$AQST $IOVA - Good morning afternoon or evening depending on where you are. Today I will start posting DD on $AQST. Tomorrow will be $IOVA DD release. Monday September XX the name of the non-biotech company and DD will be released at 9:30 am ET and throughout the day. Then on Tuesday September XX 2025 at X pm ET @TheRealDanSfera and I will have a livestream that will go in depth on the X tickers. Have a blessed weekend 🐉 family"
X Link @BIOTECHSCANNER 2025-09-27T16:27Z 7513 followers, 2981 engagements
"$AQST - I released this ticker late February of 2024. Aquestive Therapeutics is a very unique company because its a commercial stage pharmaceutical company that behaves like a clinical stage one. It has been around for XX years but their prodrug products only generate between $40M to $70M per year. They arent still not profitable even after X FDA approvals. Then Dan Barber was promoted to CEO on May XX 2022 and he has been amazing. The main drug the company was counting on to get them out of financial trouble was Libervant for seizure clusters in epilepsy. Libervant was approved BUT only"
X Link @BIOTECHSCANNER 2025-09-27T20:55Z 7513 followers, 7946 engagements
"$AQST - The future of Aquestive depends heavily on their Adrenaverse platform. Adrena refers to Adrenaline or Epinephrine. Verse means multiple or many. The company has figured out how to control the concentration and absorption of epinephrine. This opens the doors to many possibilities in various diseases since epinephrine (adrenaline) is an immune modulator meaning it can influence how the immune system responds to certain conditions. This is powerful. Anaphylm is a great example of immune modulation. After exposure to an allergen the immune system or granulated mast cells release"
X Link @BIOTECHSCANNER 2025-09-28T03:35Z 7514 followers, 3779 engagements
"$AQST - As with all pharmaceutical companies they dont randomly pick a molecule and a disease and saying lets spend $50M to $100M to see if this molecule works on it. Many of them rely on published studies from NIH (National Institutes of Health) or NCI (National Cancer Institute) or other research institutions to see initial evidence that may help them determine whether or not to pursue a particular treatment for a particular disease. A perfect example of this is Dr. Steven A. Rosenberg Chief of Surgery at the National Cancer Institute (NCI) part of the NIH. In the 1980s Dr. Rosenberg and"
X Link @BIOTECHSCANNER 2025-09-28T17:03Z 7513 followers, 2799 engagements
"$GSRT - The market cap of the modular reactor companies like $OKLO and $SMR $NNE will catch up with each other. At the current market cap of $371M $GSRT is a no brainer imo. It will at least 10x from here once more contracts are partnerships come. They will come. Remember the ticker symbol will be changed to $NKLR on Nasdaq after the merger. This will happen sometime after the vote on October X 2025"
X Link @BIOTECHSCANNER 2025-09-29T15:58Z 7513 followers, 2106 engagements
"$GSRT $IOVA $AQST - Tomorrow Tuesday September XX at X pm ET X pm CT and X PT @TheRealDanSfera and I will have a livestream to talk about these companies. I will be sharing some insights that takes too long to post on X. All three have massive catalysts coming soon. I cant wait Hope you can join us"
X Link @BIOTECHSCANNER 2025-09-30T00:53Z 7514 followers, 3969 engagements
"$IOVA - Dr. Anthony Letai sworn in as Director of National Cancer Institute (NCI). Bullish"
X Link @BIOTECHSCANNER 2025-09-30T15:02Z 7514 followers, 2462 engagements
"$AQST $GSRT $IOVA - This is by far my favorite podcast. Chris White the melanoma survivor who received Amtagvi treatment in clinical trial joined us UNEXPECTEDLY Ask yourself this question. The would the person who you followed on X because of their expertise in biotech recall a patient story from their DD or because they release XXX tickers a year and cant remember Choose wisely"
X Link @BIOTECHSCANNER 2025-10-01T00:23Z 7514 followers, 5281 engagements
"$IOVA - Bought the book This is the story of a stage X melanoma survivor who was the LAST patient admitted in the trial for Amtagvi in 2020. He joined our podcast yesterday with @TheRealDanSfera . Dan already bought the book. I already know the story but cant wait to read the book TIL therapy IS THE FUTURE of cancer treatment Why do you think many oncologists incorrectly using Amtagvi as the last line of defense instead of using it sooner Because theres NOTHING else behind Amtagvi. I believe the new mindset coming from key opinion leaders in oncology is recognizing the true benefits of"
X Link @BIOTECHSCANNER 2025-10-01T15:52Z 7519 followers, 3889 engagements
"$AQST $GSRT (NKLR) $IOVA - Have a great weekend 🐉 family. I am so freaking excited for whats coming in the next few months. Each of these X tickers can make explosive moves with positive news especially with $IOVA with X catalysts. I am warning shorts again. Every day we go deeper toward the end of the year are possibilities of PRs dropping X. NSCLC data X. Endometrial cancer data X. IOV-4001 data X. Switzerland marketing approval or application submitted X. Positive Q3 results X. Possible BUYOUT. Cant wait Lastly. I hope none of you lost your $GSRT shares but if you did learn from it"
X Link @BIOTECHSCANNER 2025-10-03T20:12Z 7514 followers, 3245 engagements
"$AQST - One of the dirty sides of Pharma is on full display. NO patient advocacy groups in the allergy community has spoken out against what ARS Pharma did in filing a citizens petition asking the FDA not to approve Anaphylm. Would you guess why This quote is a hint: The root of all evil is the love of MONEY. All of them should close up shop. Lost all respect for them"
X Link @BIOTECHSCANNER 2025-10-03T22:04Z 7513 followers, 3350 engagements
"$AQST $GSRT (NKLR) $IOVA - I love our🐉family and I made the promise since I started this community that I would never turn this into a paid service. NEVER. I dont want to turn family members into customers even though many have recommended to take my DD to other platforms and making it private so I dont take shots from trolls. For every troll there are XX awesome 🐉 members so its not a big deal. The only thing that I have requested from this community is that if you are making profits from my ideas and DD that you would kindly donate a tiny bit of that to . This is the hospital that treats"
X Link @BIOTECHSCANNER 2025-10-04T15:22Z 7514 followers, 4276 engagements
"$IOVA - I have been doing DD all day with new materials that I found and will share with you Monday morning. I am taking a quick break to tell you that NONE OF US HAS ENOUGH SHARES. I truly believe that this ticker is headed towards the teens levels again by the end of this year"
X Link @BIOTECHSCANNER 2025-10-05T00:15Z 7514 followers, 4822 engagements
"$IOVA - To make your weekend even better here is a bonus nugget: Amtagvi or any subsequent drugs approval from $IOVA wont ever go generic because its a living cell therapy. 💥💥💥Enjoy the rest of your weekend"
X Link @BIOTECHSCANNER 2025-10-05T03:21Z 7516 followers, 4599 engagements
"$IOVA - As promised heres the new DD. Much more to come Tesla is the company that supposed to have failed long ago. Today its market cap of more than $1.4T Manufacturing + scaling was a nightmare it almost went bankruptWhy didnt it Elon Musk had VISION. He wanted to change the world by demonstrating how to manufacture EVs at scale and thats EXACTLY what he did He even shared his methods to other companies Tesla did not get to profitability until the mass production of the Model X in 2016. Thats X years after the first electric vehicle rolled off Teslas manufacturing line - the Roadster. In"
X Link @BIOTECHSCANNER 2025-10-06T00:56Z 7514 followers, 4863 engagements
"$IOVA - Dips are gifts. It will come. Be patient with this one 🐉. It will go nuclear soon. We are in Q4. The last part of the 2H of 2025. The further we get into the end of the year the more condense the timing of the release of data will become. The catalysts will stack up one after another"
X Link @BIOTECHSCANNER 2025-10-06T14:09Z 7514 followers, 2301 engagements
"$IOVA - I sent this interview with Dr. Brian Gastman MD. If youre interested in investing or already invested you should definitely take a listen. As I have said before $IOVA has gone further than company has ever been before in TIL therapy. The company now has built the infrastructure for TIL manufacturing and continuing to expand. In solid cancers that makes up XX% of all new cancers theres nothing in second line Patients run out of options quickly after checkpoint inhibitors. Not anymore. Amtagvi has demonstrated amazing efficacy that is more than anyone thought possible. $IOVA is saving"
X Link @BIOTECHSCANNER 2025-10-06T15:16Z 7514 followers, 2113 engagements
"$IOVA - Science refused to let us die young. Its all about the science. TIL therapy is the present and future of cell therapy in solid tumors. Maybe in blood cancers in the future too The company is continuously finding new ways to improve their technology to make TIL treatment more effective. Science"
X Link @BIOTECHSCANNER 2025-10-06T15:54Z 7514 followers, 2173 engagements
"$IOVA - TIL therapy is the future"
X Link @BIOTECHSCANNER 2025-10-06T16:38Z 7514 followers, 2378 engagements
"$GSRT $IOVA $AQST - There is one message I post more often than anything else that I put out there. That is PATIENCE I pounded the table on these companies and provided in depth DD. They all will have their own run at some point. I dont know when the run up will come but the only thing I do consistently is to add on dips. If there is a secret recipe to success it is that Be patient and add on dips. Do this only after your conviction is backed by your research"
X Link @BIOTECHSCANNER 2025-10-06T18:14Z 7514 followers, 3375 engagements
"$IOVA - Immune Checkpoint Inhibitors like these: Anti-PD-1 : Pembrolizumab (Keytruda )nivolumab cemiplimab Anti-PD-L1 : Atezolizumab durvalumab avelumab Anti-CTLA-4 inhibitors: Ipilimumab They are amazing IN FRONTLINE for solid cancers. Unfortunately cancer progression occurs in more than XX% of patients. Besides brutal chemotherapy with X% or less ORR in 2L solid tumors. Theres nothing else. This statistic is also true with metastatic melanoma. Patients ran out of options. Then comes Amtagvi. How did it do in the clinical trial that got its FDA approval in second line metastatic melanoma"
X Link @BIOTECHSCANNER 2025-10-06T19:38Z 7514 followers, 2045 engagements
"$IOVA - This is such a great conference to listen to. EVERYTHING is in here. CFO Corleen Roche and EVP Medical Affairs Brian Gastman MD talk about revenue restructuring relationship and constant communication with the FDA hiring former FDA experts clinical trials possible trials data release methods and timing pipeline and competitive landscape. Just like $GSRT investors day video I warn you that if you listen to this you will want to get more shares. Guaranteed. Dont listen to it unless you have dry powder 😆"
X Link @BIOTECHSCANNER 2025-10-06T22:57Z 7514 followers, 2253 engagements
"$IOVA - Iovance Biotherapeutics brought in the big guns with decades of experience at the FDA. Why $IOVA has a massive pipeline with multiple TIL treatments for numerous types of cancers. Think about how his relationships with the FDA will benefit $IOVA and the patients ultimately. This is an amazing hire: Raj K. Puri M.D. Ph.D. Chief Regulatory Officer Dr. Puri joined Iovance in March 2022 as Executive Vice President Regulatory Strategy and Translational Medicine. Dr. Puri was promoted to Chief Regulatory Officer on November XX 2024. He has decades of experience with the evaluation and"
X Link @BIOTECHSCANNER 2025-10-07T00:47Z 7514 followers, 2345 engagements
"$IOVA - This Cell & Gene meeting in Phoenix AZ on October 6-8 is massive So many big and small biotech companies attending Iovance has two panelist experts on two different general sessions Iovance is getting lots of visibility here. Why not No companies have made it this far in TIL therapy Dan Kirby Chief Operating Officer and Laurel Todd - Head of Policy and Market Access Operations will be the panelists"
X Link @BIOTECHSCANNER 2025-10-07T02:08Z 7514 followers, 2279 engagements
"$IOVA - Big day at a big Cell & Gene Therapy conference in Phoenix AZ"
X Link @BIOTECHSCANNER 2025-10-07T13:27Z 7514 followers, 3458 engagements
"$IOVA - Cell & Gene Therapy market to grow exponentially in the next X years. CCO Dan Kirby will be on stage today"
X Link @BIOTECHSCANNER 2025-10-07T13:52Z 7514 followers, 4278 engagements
"$IOVA - We are currently waiting on updated data on second line 2L Non-Small Cell Lung Cancer (NSCLC) endometrial cancer and IOV-4001 in 2L melanoma. While we are waiting lets take a look at how Amtagvi does in combination with Pembrolizumab (Keytruda) in frontline immune checkpoint inhibitor naive patients shall we As you know NSCLC is deadly. After the patient moves to second line fatality is around 80%. 125K deaths in the US and XXX globally per year. The unmet need is gigantic as you can see. How did Amtagvi do in combination with this amazing drug called Pembrolizumab (Keytruda in"
X Link @BIOTECHSCANNER 2025-10-07T15:50Z 7514 followers, 4139 engagements
"$IOVA - When positive data (I dont miss) are presented for: X. NSCLC 2L X. Endometrial Cancer 2L X. Next generation TIL (PD-1 Inactivated) in 2L metastatic melanoma Where will you be Are you on the 🚀 or are you admiring it from the afar Everything is right under our noses this whole time. Just look at how Amtagvi is kicking ass in stage X metastatic melanoma. One of the deadliest cancers out there and its getting: Among XX evaluable patients treated at four authorized treatment centers the physician-assessed objective response rate (ORR) was XXXX% (20/41). Response rates with Amtagvi were"
X Link @BIOTECHSCANNER 2025-10-07T22:42Z 7518 followers, 4621 engagements
"$AQST - XX more years of patent protection Anaphylm will capture at least XX% of the market"
X Link @BIOTECHSCANNER 2025-10-08T13:05Z 7514 followers, 2799 engagements
"$IOVA - The combination of making large community hospitals and the partnership with InspiroGene by McKesson is a game changer. They are a specialty pharmacy that specializes in complicated treatments and get authorization for the patients X. Oncologists now dont have to send patients to another ATC. They can treat them right at the same hospital. X. Oncologists can start patients on Amtagvi as soon as first line treatments fail them. X. Healthier patients respond much better to Amtagvi treatment thus improving their survival chances. Remember these patients run out of options fast after"
X Link @BIOTECHSCANNER 2025-10-08T14:28Z 7514 followers, 2513 engagements
"$GSRT - As expected the merger is approved. I am still waiting on when the official ticker change will take place. $NKLR what a name Love this company Will keep you posted"
X Link @BIOTECHSCANNER 2025-10-08T14:31Z 7514 followers, 3641 engagements
"@mhelvz12 I have done several podcasts with a fellow $IOVA investor @TheRealDanSfera. I cover $IOVA quite a bit on there as well. We did one on Tuesday September XX. We will have a special one on $IOVA pretty soon with Chris White the cancer survivor"
X Link @BIOTECHSCANNER 2025-10-09T02:13Z 7514 followers, XXX engagements
"@Will_M_Straya Be prepared for 5x that with $IOVA"
X Link @BIOTECHSCANNER 2025-10-09T14:18Z 7514 followers, XXX engagements
"$AQST - Do you know how many 🪳🪳 called me pumper scammer when I was posting scientifically based DD when the share price dropped to $XXXX at one point this year Did I stop posting No Research based conviction my 🐉🐉🐉. Where are they now"
X Link @BIOTECHSCANNER 2025-10-09T16:18Z 7514 followers, 2934 engagements
"$IOVA $NKLR $AQST If $NKLR goes nuclear (it will at some point) then $IOVA will go supernova on us. $AQST still could double from here. 🚀🚀🚀"
X Link @BIOTECHSCANNER 2025-10-09T21:38Z 7515 followers, 2021 engagements
"I have no idea but remember that they have a lot of shares too. Management personnel are shareholders as well. I said the same thing about $AQST. People were worried about dilution. The company will do what is best to move the company forward. That would benefit all of us and the company. They announced the shelf and will tap when needed. All good companies do. ASTS RKLB AQST. The massive catalysts will be definitely present an opportunity. But with a shelf we probably wont know it until they announce during earnings. No worries there for me"
X Link @BIOTECHSCANNER 2025-10-09T23:26Z 7514 followers, XXX engagements
"$AQST - Dead On Arrival (DOA) will be the final destination of this new option along with Neffy. Belhaven Biopharma will become BelHELL Biopharma. The company is missing the point. Get rid of the device The only way to do that is using the film- Anaphylm The only way to increase the carry curve is to not have a bulky device. This is a bad idea"
X Link @BIOTECHSCANNER 2025-10-10T02:58Z 7515 followers, 2555 engagements
"$IOVA - Corleen Roche CFO when answering the question of what drew her to Iovance even though she has a long track record at some large companies like Pfizer and Biogen and CG Oncology said I am very excited to be here and tell you all the good things that drew me to Iovance. Number X we cant forget the product is good its on the market and its helping people. Thats the most important thing. I believe the company is in good hands with her. Corleen Roche is very frank and honest. She has launched some big drugs before. Im very impressed by her previous success. Patience 🐉"
X Link @BIOTECHSCANNER 2025-10-10T19:54Z 7517 followers, 2628 engagements
"@dan_glinert $IOVA - Iovance will have Merck AstraZeneca and BMY drooling soon. The NSCLC market is so big"
X Link @BIOTECHSCANNER 2025-10-10T20:57Z 7514 followers, XXX engagements
"$NKLR - This will never get old 🤑"
X Link @BIOTECHSCANNER 2025-10-13T20:04Z 7516 followers, 4159 engagements
"$IOVA $NKLR - If you think $NKLR is explosive just wait until $IOVA releases data coming any day now on NSCLC endometrial cancer and next generation TIL IOV-4001 in second line metastatic melanoma. Current sitting at around $X I believe we may see $10-$12 especially with positive Q3 earnings. I believe theres a XXXX% chance that NSCLC will be positive and the company will use it as part of the accelerated FDA approval. Dont miss this one. I dont miss on data results prediction either"
X Link @BIOTECHSCANNER 2025-10-13T21:32Z 7514 followers, 4147 engagements
"$IOVA - There is no name that is bigger than McKesson in healthcare services and distribution. It distributes pharmaceuticals medical-surgical supplies and provides healthcare technology solutions. By partnering with InspiroGene by McKesson more patients can get Amtagvi. This is a massive game changer. If there is one thing I know well about the pharmaceutical industry this is it No matter how good the drug is if the insurance approval process is too complicated the prescription will not be filled InspiroGene will leverage Biologics by McKessons more than XX years of specialty pharmacy and"
X Link @BIOTECHSCANNER 2025-10-15T02:10Z 7514 followers, 2706 engagements
"$IOVA - So apparently I know what I was talking about when I said the partnership with InspiroGene by McKesson is a game changer. XX years of pharmaceutical experience 🐉. Thats what you get from me. Free"
X Link @BIOTECHSCANNER 2025-10-15T14:20Z 7515 followers, 2568 engagements
"$IOVA - This is a must watch podcast. Thank you @MucosalMelanoma and @TheRealDanSfera for an amazing interview Thanks again to those who watched the podcast"
X Link @BIOTECHSCANNER 2025-10-16T02:09Z 7517 followers, 4713 engagements
"@PrasaiManish @MucosalMelanoma @TheRealDanSfera Stunning. Once $IOVA gets back to $XX and it will lets get organize a trip there. 😀"
X Link @BIOTECHSCANNER 2025-10-16T05:15Z 7517 followers, XXX engagements
"I have said it before that diversification in biotech is not a good idea. Find X or two and invest if you have very strong conviction in them. Many times I only have X in my portfolio. My percentage is much higher than XX% for $IOVA. Nothing goes in a straight line. But good companies will eventually rise to the top. People will dwell on the past and thats great for us. We get in at these ridiculously low prices. Good luck to you as well"
X Link @BIOTECHSCANNER 2025-10-16T13:25Z 7519 followers, XXX engagements
"Its $560K now. Was raised in April. Proleukin is $60-100K depending the patient weight. Key Opinion Leaders (KOLs) are telling everyone to start Amtagvi as soon as frontline treatments failed. Its coming together. Thanks for your contribution to the community by providing good information"
X Link @BIOTECHSCANNER 2025-10-16T17:42Z 7514 followers, XX engagements
"@Cricket99238 $VKTX was my very first release in December 2023 Released it under $XX and it got to $XXXXX about X months later Thats my specialty. I launched Ozempic with Novo Nordisk"
X Link @BIOTECHSCANNER 2025-10-17T03:50Z 7509 followers, XXX engagements
"@TrumpoKim I think they have a plan to destroy shorts by the way they are talking. The CFO mentioned the stock price. They are aware that the stock price is suppressed. If the data is good the month doesnt matter. However the longer they wait to cut off data the better the DOR will look"
X Link @BIOTECHSCANNER 2025-10-18T18:02Z 7518 followers, XXX engagements
"@meputzke20 You can ask me here. Maybe these questions can help the community learn more about $IOVA. This is the standard that I have set. If I dont know the answer I would say so also"
X Link @BIOTECHSCANNER 2025-10-19T20:09Z 7517 followers, XXX engagements
"$IOVA - Just added more for my wifes account. My daughters account has quite a few shares as well now. Any divorce lawyers in 🐉 family 😂. Unbelievably cheap at this price"
X Link @BIOTECHSCANNER 2025-10-10T18:21Z 7517 followers, 3195 engagements
"$IOVA - Abivax $ABVX with a current market cap at around $7B was trading at $XX on July XX 2025. Then after hours a PR arrived with this headline: Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 Enhancer in Moderate to Severely Active Ulcerative Colitis The next day July XX 2025 it rose to $XXXXX. We are waiting on not X not X but X separate clinical trials data on NSCLC endometrial cancer and melanoma. The total addressable market for just NSCLC alone is already much higher than ulcerative colitis So"
X Link @BIOTECHSCANNER 2025-10-14T01:38Z 7517 followers, 5724 engagements
"$IOVA - Apparently I called it again. Yesterday I said the company wont release any of the new data that was supposed to be released in 2H of 2025 at the up coming conferences. Here are the two conferences remaining this year. Society for Immunotherapy of Cancer (SITC) 2025 is on November 7-9 in National Harbor Maryland . European Society for Medical Oncology (ESMO) 2025 Congress will be held October 17-21 2025 in Berlin Germany. These are pretty large conferences that will wrap up 2025. The big one ASCO 2026 is not until next year. The biggest oncology conference is The American Society of"
X Link @BIOTECHSCANNER 2025-10-18T16:44Z 7517 followers, 4593 engagements
"$IOVA - This is EVP Medical Affairs Brian Gastman MD speaking at the Barclays Healthcare Conference back in March of 2025. Unfortunately the recording is no longer available but heres part of what he said about NSCLC data: Hmmm"
X Link @BIOTECHSCANNER 2025-10-20T17:22Z 7517 followers, 2316 engagements
"$IOVA - Look at how amazing Amtagvi is doing outside of clinical trials and in the real world. Many physicians believe clinical trials are rigged in favor of the drug. But this isnt a clinical trial. These are results compiled from patients who have been treated with Amtagvi and followed them for X years Remember these patients were planning their funerals my friends. Look at what happens to the tumor burden (how much cancer is still in the body). X weeks after Amtagvi treatment and bam Where did it go I have been in the pharmaceutical industry for XX years. I have never seen a company with a"
X Link @BIOTECHSCANNER 2025-10-14T22:54Z 7517 followers, 3534 engagements
"$IOVA - Buying $IOVA shares now is like buying shares in Tesla when it produces its first EV the Tesla Roadster. Tesla was losing money selling its roadster because manufacturing was expensive. It would have gone bankrupt if it stopped innovating and keeps making only Roadsters on the same assembly lines. Is that what Tesla did Or did it fine tune manufacturing and made numerous other models after the Roadster Tesla did not reach profitability until 2013 with Model S. Consistent profitability did not come until Model X Amtagvi is basically the Roadster for Iovance Except $IOVA can reach"
X Link @BIOTECHSCANNER 2025-10-16T16:54Z 7517 followers, 4286 engagements
"$IOVA- We dont have enough shares"
X Link @BIOTECHSCANNER 2025-10-16T22:08Z 7517 followers, 1911 engagements
"$IOVA - By the way I have never missed on data predictions- good or bad. Go back and check. My most recent prediction was someone privately asked me if he should load VKTX before oral VK2735 data. I told him data will be just ok and a big drop will happen BECAUSE THE EXPECTATION WAS TOO HIGH. Not because of the drug. Bam. Exactly as I predicted. He can confirm this if he chooses. I have predicted many positive results before they were released and they all came out as I thought they would. This is not to brag. This is to tell you that hours of research and years of experience help me form my"
X Link @BIOTECHSCANNER 2025-10-17T03:22Z 7517 followers, 4357 engagements
"@FdetranaY It will be fun brother. People forget how bad they felt when $AQST was below $X just a year ago. $IOVA will be in double digits soon"
X Link @BIOTECHSCANNER 2025-10-17T18:11Z 7517 followers, XXX engagements
"@Henry431171040 Is this pain similar to when $AQST was under $X Patience my friend. Soon"
X Link @BIOTECHSCANNER 2025-10-17T18:13Z 7517 followers, XXX engagements
"Have a great weekend 🐉 family. I hope you will spend lots of quality time with your loved ones and cherish every moment Life is very precious yet extremely fragile. Investing in $IOVA and $AQST makes me appreciate life even more. Get rejuvenated and get ready for another exciting week on Monday To those who have invested in $IOVA I know what you have been thinking . Stop it. 😂"
X Link @BIOTECHSCANNER 2025-10-17T22:24Z 7517 followers, 2512 engagements
"$IOVA - What is the future of TIL The treatment is complicated toxic and expensive. Listen to this podcast and you can hear and learn from Dr. Kelly Mahuron from City of Hope. Notice how Iovance rolls off her tongue like a household name as predicted byme😂. Toward the end of the podcast a question was raised about the future of TIL. Why TIL Because nothing is better right now. People still think of TIL as a static platform for cell therapy. Its the opposite The TIL space is very dynamic What How Did you know that Iovance is working on the next generation TIL and next generation IL-2 and even"
X Link @BIOTECHSCANNER 2025-10-18T22:12Z 7517 followers, 2678 engagements
"$IOVA - Before I release more DD I just wanted to say: We dont have enough shares of this bottomed out stock🐉fam"
X Link @BIOTECHSCANNER 2025-10-19T18:16Z 7517 followers, 3719 engagements
"With the current FDA explicitly taking a Made in USA stance based on national security concerns be careful investing in companies that conduct clinical trials in China. The FDA will make companies redo trials in the US or at least Europe. I wholeheartedly agree with Dr. Makary and Dr. Prasad on this point. You have no idea the depth of corruption in these countries. Its REALLY BAD. #SMMT"
X Link @BIOTECHSCANNER 2025-10-19T19:50Z 7517 followers, 2647 engagements
"$IOVA - Patience 🤑🤑🤑. This is the #1 biotech from now until the rest of the year. Looking further 2026 will be incredible as the company anticipates multiple exUS approvals supplemental application (sNDA) for Amtagvi in second line NSCLC IND applications (Investigational New Drug) for IOV-5001 next generation TIL for multiple types of solid cancers and second line NSCLC with next generation TIL IOV-4001 as well as next generation IL-2. We should also be getting interim data on frontline metastatic melanoma and NSCLC in the second half of 2026. This is the one 🐉🐉🐉. This is the one. But"
X Link @BIOTECHSCANNER 2025-10-19T23:38Z 7517 followers, 3445 engagements
"@Henry431171040 @TrumpoKim @FdetranaY It wont make that far before Merck Bristol Myers or AstraZeneca bought it. $10B is the price that I believe $IOVA will be sold. But it has to show progress with sales and margins before it gets a buyer. It will be a much better company soon"
X Link @BIOTECHSCANNER 2025-10-20T02:23Z 7517 followers, XXX engagements
"@FdetranaY @n_hatami @OldGoldHawkeye @Henry431171040 @TrumpoKim Most biotech investors would dream of a NSCLC data as a big catalyst. $IOVA has X additional ones (endometrial cancer and metastatic melanoma). Very exciting times ahead indeed"
X Link @BIOTECHSCANNER 2025-10-20T19:25Z 7517 followers, XXX engagements
"$IOVA - EU approval is imminent. NSCLC data with a massive addressable market of $66BN is expected in 2H. Shorts are playing with fire and will be smoked. Amtagvi one time treatment has consistently shown tremendous success in wiping out tumors in even hardest to treat population. Easy 10x potential here with patience. We are at the very bottom. Trading almost at cash value. No brainer for me"
X Link @BIOTECHSCANNER 2025-06-03T14:18Z 7518 followers, 2221 engagements
"$IOVA - This is Toni English and her testimony on her cancer journey. In 2015 she was diagnosed with Stage X Sinonasal Mucosal Melanoma a very rare and aggressive subtype of melanoma and given X months to live. One year later routine scans showed metastases to my brain both lungs and a kidney. After receiving Amtagvi in clinical trial like Chris White Tonis scans show No Evidence of Disease (NED). But the biggest question I have is what happened to the cancers that spread to the brain lungs and liver How do you think NSCLC data will look I think its going to be amazing Patience"
X Link @BIOTECHSCANNER 2025-10-06T20:19Z 7518 followers, 3008 engagements
"$IOVA - Did anyone catch what Tonis oncologists told her Here: I was offered a clinical trial that could potentially kill all of my cancer. ALL Then what happened Toni after X months my cancer was gone My scans continue to show NED( No Evidence of Disease). Her oncologists knew about TIL therapy years before Amtagvi was approved. This is why I dont go to doctors who are not up to date on the latest technologies. Her doctors saved her life with the help of Amtagvi. What I am also so impressed about was her oncologists recognizing the potential of Amtagvi to KILL ALL OF HER CANCER (Melanoma"
X Link @BIOTECHSCANNER 2025-10-06T22:00Z 7518 followers, 2557 engagements
"$IOVA - X of these days pre-market or after market PR will announce a buyout from X of the X BPs"
X Link @BIOTECHSCANNER 2025-10-07T03:27Z 7517 followers, 5107 engagements
"$IOVA - Laurel Todd Head of Policy and Market Access is speaking today at the Cell &Gene Meeting On The Mesa. She is probably the third most important person in the company. Market Access is EVERYTHING when launching a product. Dan Kirby Chief Commercial Officer CCO spoke yesterday at this huge conference in Phoenix AZ"
X Link @BIOTECHSCANNER 2025-10-08T12:57Z 7517 followers, 3926 engagements
"$IOVA - Iovance Biotherapeutics knows that Amtagvi is just the beginning of TIL therapy. The company doesnt sit around and watch Amtagvi kicking stage X metastatic melanoma in the ass. It is constantly trying to improve its products to fight cancer. Why Because cancers dont sit around either It gets stronger. It mutates to hide and deceive the immune system. Iovance Biotherapeutics chose to fight solid tumors while big pharma wants to make money by pouring money into CAR-T because its easier than TIL. Guess which treatment is better for fighting cancer CAR-T is only ok with blood cancers that"
X Link @BIOTECHSCANNER 2025-10-08T14:45Z 7517 followers, 2953 engagements
"$IOVA - Do not watch this unless you have dry powder to get more shares. Pay attention to the addressable markets in frontline and second lines of Melanoma NSCLC and endometrial cancer. You all have had a chance to load under $X. This is the most exciting biotech company for the next X years at least. It will be in the teens"
X Link @BIOTECHSCANNER 2025-10-08T19:52Z 7517 followers, 2899 engagements
"$IOVA - There are approximately 8K patients for second line metastatic melanoma in the US. Remember theres nothing else besides chemotherapy in second line. If Amtagvi gets XXX% of the market share thats $XXX billion. But they wont get the entire market. At XX% that is about $X billion. At XX% $X billion. Now add about $80k of IL-2 in there as well. Again Amtagvi has a monopoly in 2L metastatic melanoma This is why I said the company will be more than profitable with just Amtagvi in 2L in the US market alone. The company is also conducting TILVANCE XXX to serve X purposes. X as a confirmatory"
X Link @BIOTECHSCANNER 2025-10-08T22:13Z 7517 followers, 2945 engagements
"$IOVA $AQST $GSRT ($NKLR) This is my pinned message when you look at my profile. For biotech $IOVA and $AQST they check many of the boxes. $GSRT even though its not a biotech it also checks many boxes too Here it is: How to identify great biotech companies X. Undervalued (low market cap vs assets and market potential) X. Solid management (biotech experience CEO track record and reputation not too many turnovers) X. Great pipeline versus whats currently available (look for first and only or best in class potential. X. Solving a big unmet need X. Incremental successes through various stages of"
X Link @BIOTECHSCANNER 2025-10-09T00:14Z 7517 followers, 2624 engagements
"$IOVA - Chris White who wrote Killing Cancer with TILs will be on stage to share his testimony on how Amtagvi saved his life from the brink of death at the GLOBAL CANCER RESEARCH AND INNOVATION SYMPOSIUM on October 21st in NYC on behalf of Alliance for Cancer Gene Therapy. Guess what message hes going to share Hes going to say why did his team of oncologists waited SO LONG to recommend him to the clinical trial in 2020. Hes encouraging physicians to recommend Amtagvi SOONER AND HE IS NOT GETTING PAID BY $IOVA. How powerful is that It has to be about the drug as the starting point to invest in"
X Link @BIOTECHSCANNER 2025-10-09T01:36Z 7517 followers, 2741 engagements
"$IOVA - I just finished reading this book and all I can say is WOW. This book is written without using an editor. You will see numerous spelling grammar and at one point a section was added twice. But Chris White warned the readers at the beginning to expect these errors. Im totally fine with it. Im not going to spoil it for you but I can hint that if this book were a song the most beautiful and powerful part involves the main reason you would invest in $IOVA. I have been in this industry for XX years. I have never witnessed a pharmaceutical company with a treatment platform this good and not"
X Link @BIOTECHSCANNER 2025-10-09T04:50Z 7517 followers, 2378 engagements
"$IOVA - How do you think these insiders feel about the up coming data releases for NSCLC endometrial cancer and next generation TIL IOV-4001 Hmm"
X Link @BIOTECHSCANNER 2025-10-09T13:55Z 7517 followers, 3639 engagements
"$IOVA - The company is set to release updated interim data for Amtagvi in second line (2L) NSCLC for patients who have gotten worse on chemotherapy and anti PD-1 before the year ends. July X 2023 was the cutoff date for the previous preliminary data that was released on July XX 2023. This recent data cut included XX NSCLC patients treated with LN-145. An ORR of XXXX% by RECIST v1.1 (n=6 one complete response and five partial responses) was observed with a disease control rate of 82.6%. While still early on study the median duration of response (DOR) was not reached. The DOR ranged from 1.4+"
X Link @BIOTECHSCANNER 2025-10-09T15:56Z 7517 followers, 2668 engagements
"$IOVA - Big Pharma focuses on the big money. Always Wheres the big money Non-Small Cell Lung Cancer (NSCLC) is where its at. Even in second line the market is massive. Then when you add frontline to the equation big pharma drools. If 2L NSCLC data is positive and I believe it will be $IOVA will become a very hot commodity in biotech. It will further solidify its leadership in TIL therapy. $IOVA has a monopoly in TIL therapy. Look at the addressable market and see it for yourself and also see how Amtagvi demonstrated in preliminary analysis in second line and frontline NSCLC. X pictures"
X Link @BIOTECHSCANNER 2025-10-09T17:03Z 7517 followers, 2603 engagements
"$AQST $IOVA $GSRT - This is a humbling post and I appreciate the kind words from a 🐉 family member. Its not easy I can tell you especially when several people turned against me JUST BECAUSE THE SHARE PRICE DROPPED. Not anything else. This is what happens when they dont do research and totally put the responsibility on me for their investments. Oh did they missed out on this opportunity and look foolish in the process. Patience is a virtue and so as kindness. Thank you @NLeounakis"
X Link @BIOTECHSCANNER 2025-10-09T17:53Z 7517 followers, 2881 engagements
"$IOVA - After hiring one of the big guns at the FDA in Dr. Raj Puri who joined Iovance in March 2022 as Executive Vice President Regulatory Strategy and Translational Medicine. Dr. Puri was promoted to Chief Regulatory Officer on November XX 2024. Then on July XX 2025 $IOVA announced another former FDA leader with the appointment of Marc. R Theoret M.D. to assume the newly created position of Senior Vice President Regulatory Strategy where he will focus on clinical regulatory strategy for Iovances pipeline. Effective immediately Dr. Theoret will report to Dr. Raj K. Puri M.D. Ph.D. Chief"
X Link @BIOTECHSCANNER 2025-10-09T18:42Z 7517 followers, 3409 engagements
"$IOVA - I am having a major case of Deja Vu. Pounding the table when $IOVA is at bottoms and trading at near cash levels like I did with $AQST at $XXXX. As you can see patience 🤑"
X Link @BIOTECHSCANNER 2025-10-09T22:32Z 7517 followers, 2758 engagements
"$IOVA - Earlier today I posted about the hiring of former FDA leaders Dr. Raj Puri and Dr. Marc Theoret to Iovance Biotherapeutics to focus on Regulatory Strategy.This is a very smart move. Currently they have an amazing working relationship with the FDA. As a matter of fact EVERY TRIAL DESIGNS is done with the FDA and in the case of the Frontline Melanoma and confirmatory trial in 2L melanoma for Amtagvi TILVANCE XXX also with the European Medicines Agency (EMA). This was discussed during the Wells Fargo conference with CFO Corleen Roche and EVP Brian Gastman MD at minute XX. I highly"
X Link @BIOTECHSCANNER 2025-10-10T00:52Z 7517 followers, 3075 engagements
"@Cricket99238 This is why I tell people if you INVEST you have to stay calm and add on red days. Iovance is 10x better than Orbital Tx. Massive opportunity for investors to invest in $IOVA"
X Link @BIOTECHSCANNER 2025-10-10T16:29Z 7517 followers, XXX engagements
"$IOVA $AQST - These have nothing to do with tariffs by the way 😀"
X Link @BIOTECHSCANNER 2025-10-10T16:31Z 7517 followers, 2625 engagements
"$IOVA $AQST $NKLR - All X tickers would have been green yesterday if it werent for a post from the President. I cant stress enough that investing is mostly about mental toughness. There are constantly noises around whether from the macro or micro economic environment or from shorts who live in fear especially if a company has multiple catalysts coming like $IOVA. They have to continually create fear and panic. In these moments we have to lean back to our original thesis on the company that we invested in and asking tough questions like we should. Has anything changed that makes us want to"
X Link @BIOTECHSCANNER 2025-10-11T17:21Z 7517 followers, 9660 engagements
"Yes I have I agree with the fact that it is a long term investment if you want 10x returns in $IOVA. If everything goes well in X years it will be much higher than 5x. Key here is patience. They have something that nobody else has. The TIL market is extremely difficult to get into. Their manufacturing is set. Think about it. XX% of cancers are solid tumors. BP are chasing CAR-T for blood cancers that make up the other 9%. I will take a chance with the bigger market that is 10x bigger. ANY DAY"
X Link @BIOTECHSCANNER 2025-10-12T14:36Z 7517 followers, 1013 engagements
"$IOVA - Did you know Genesis merged with Lion and later became a dragon (adopted by the 🐉 family) named Iovance. The name reflects its vision to focus on the advancement of immuno-oncology (I/O + advance). Remember the name Lion. Now you know. 😀"
X Link @BIOTECHSCANNER 2025-10-12T14:57Z 7517 followers, 2399 engagements
"$IOVA $AQST $NKLR - External negative sentiments tend to have a piling on effect. When a stock price drops the bears pile on even more. You should know this by now. This is the main reason I dont go on StockTwits. If you want to be an investor with sound mind dont go on ST. Why do I say this Because even if you dont want to admit or thinking it wont affect you it does. The majority of shorts will go on these platforms to scare you. Thats what they do Their existence depends on the stock price dropping They have a huge incentive to create fear uncertainty and doubt Let me share with you my"
X Link @BIOTECHSCANNER 2025-10-12T16:54Z 7517 followers, 3306 engagements
"@SantinoD261015 I bought a lot of $IOVA for my wifes account so this may get complicated 🤣"
X Link @BIOTECHSCANNER 2025-10-12T20:00Z 7517 followers, XXX engagements
"$IOVA - The most important pioneer in tumor-infiltrating lymphocyte (TIL) therapy for cancer. Its come a long way. Thanks to Dr. Steven Rosenberg at the National Cancer Institute (NCI) who came up with the original idea of TIL therapy. The company was founded in 2007 and originally called Genesis Biopharma Inc. in California with the initial focus on developing personalized cell therapies for solid tumors using TIL (tumor-infiltrating lymphocytes) technology. As previously stated the TIL concept came from work at the U.S. National Cancer Institute (NCI) under Dr. Steven Rosenberg a pioneer in"
X Link @BIOTECHSCANNER 2025-10-12T22:52Z 7517 followers, 3549 engagements
"$IOVA $NKLR $AQST - Guess what Per CNBC Stock futures rebound from Fridays rout after Trump says China situation will all be fine 😂"
X Link @BIOTECHSCANNER 2025-10-12T23:45Z 7517 followers, 4896 engagements
"$IOVA - What if I told you that theres a person who was treated with lifileucel (AMTAGVI) in 2013 when Iovance Biotherapeutics was still called Lion Biotechnologies by the inventor of TIL (Tumor Infiltrating Lymphocytes) therapy Dr. Steven Rosenberg himself; and XX years later hes still a complete responder (CR) with NO EVIDENCE OF DISEASE (NED) This person is Bill Heyman. He recently was interviewed by another complete responder Chris White on TIL TALKS. If you think Chris Whites story is amazing then youre in for another treat. This story has a very moving moment that involves Dr. Steven"
X Link @BIOTECHSCANNER 2025-10-13T02:09Z 7517 followers, 6931 engagements
"$IOVA - Anne Brooks will be in Philadelphia to participate in Keynote Panel Discussion: State of the Industry Address for Cell and Gene Therapies on November XX. This is what happens when you are the leader in cell therapy. People want to know and learn from you the good and the bad. $IOVA revenue increased XX% from Q1 to Q2. This is the type of progress that we want to see. I expect similar or better growth in Q3 with higher margins. The community hospitals becoming their own ATCs (Authorized Treatment Centers) is a huge deal for several reasons: X. The patients at community hospitals are"
X Link @BIOTECHSCANNER 2025-10-13T14:49Z 7517 followers, 2646 engagements
"$IOVA $AQST $NKLR You k know what people were saying about $PLTR a couple of years ago when the share price was around $X at the beginning of January 2023 X. They are losing money like crazy X. They are diluting. X. Business not growing X. Business model is too complicated X. What the hell do they do These are the same people who quietly loaded while saying these things. $PLTR is trading at $XXX today. Shorts want you to expect current revenue from $PLTR but should only be paying $X per share. They do this EVERYDAY. They are everywhere. These are the people who tell you that you can enjoy the"
X Link @BIOTECHSCANNER 2025-10-13T15:44Z 7517 followers, 3521 engagements
"$IOVA - Each day that goes by the timeline is more condensed for these catalysts. There are X sets of data and X events that will be released and occur by year end: X. Non-Small Cell Lung Cancer (NSCLC) - The death rate in the US alone is staggering at 125K per year. Globally its even worse at XXX million per year. No options except chemotherapy and combination with other checkpoint inhibitors that are not effective. The fatality rate is more than XX times higher than melanoma. The patient population is massive. Second line NSCLC indication alone makes $IOVA the envy of the entire cell"
X Link @BIOTECHSCANNER 2025-10-13T18:19Z 7517 followers, 2985 engagements
"@Cricket99238 Even if I didnt invest in $IOVA I would still wholeheartedly rooting for it to succeed. Who wouldnt Since I am an investor its even easier for me to support its causes 😀. Its going to be fun here soon"
X Link @BIOTECHSCANNER 2025-10-13T20:57Z 7517 followers, XXX engagements
"@RosenzweigDMD Management is now a strength. CFO Corleen Roche doesnt mess around. She immediately throws the previous CFO under the bus because he misguided into a brand new market. Shes correct. $450M to $475M was too aggressive. $IOVA will be in great shape"
X Link @BIOTECHSCANNER 2025-10-13T23:08Z 7517 followers, XXX engagements
"@biotechreviews Holy moly. Yep I am not surprised. Is there anything better than a new treatment for NSCLC right now Especially when theres none You see why I am saying what I have been saying I am being VERY conservative when I said $10-$12 from current levels for $IOVA. This is biotech"
X Link @BIOTECHSCANNER 2025-10-14T00:50Z 7517 followers, XXX engagements
"$IOVA - Amtagvi treatment is saving lives and every day the good news is being shared. This ATC (Authorized Treatment Center) has treated over XX patients and is encouraging oncologists to refer patients to them This ATC is in Atlanta Georgia. Thank you @yss4318 for sending this to me. As the saying goes If you build it they will come. $IOVA has an amazing product in Amtagvi. Due to the complicated nature of the treatment the roll out has been slower than anticipated. But the ball is rolling and is picking up momentum. Amtagvi is a tough treatment to receive because cancer is also tough and"
X Link @BIOTECHSCANNER 2025-10-14T14:22Z 7516 followers, 4218 engagements
"$IOVA - What is The National Comprehensive Cancer Network (NCCN) It is a nonprofit alliance of XX leading U.S. cancer centers including MD Anderson Memorial Sloan Kettering and Dana-Farber that develops widely used clinical practice guidelines for cancer care. NCCNs main work is creating and maintaining evidence-based treatment guidelines for almost every cancer type.These guidelines are used by oncologists insurers and regulatory agencies to decide: X. What the standard of care treatments are. X. When a therapy is appropriate (first line second line etc.) a. How to sequence therapies b. How"
X Link @BIOTECHSCANNER 2025-10-14T16:03Z 7516 followers, 2827 engagements
"$IOVA - This is the order of PRs that I am hoping we will be getting: X. Q3 earnings💥 X. Switzerland approval💥 X. Endometrial cancer data💥 X. IOV 4001 data for melanoma 💥 X. NCSLC data💥 The company has mentioned that they want to let the data matured because of the exceptional durability of the TIL treatment that will favor Duration of Response (DOR). So maybe we will get X sets of data in December. I am completely cool with that. But if Q3 earnings is positive the stage is set for potentially the biggest runner in biotech this year with X catalysts. If you are waiting on X catalyst its"
X Link @BIOTECHSCANNER 2025-10-14T20:43Z 7516 followers, 4402 engagements
"$IOVA - Chemotherapy combos in second line NSCLC get about X% ORR. They are pathetic. You want to talk about a low bar and the extremely high unmet need in this population Society desperately needs Amtagvi to get approved ASAP if the ORR is XX% or above and DOR is X months or above. 125K deaths in the US and XXX million deaths globally per year. And its only gotten worse Data from 2023 already showing ORR XXXX% (6/23); DOR XX% of confirmed responders had responses lasting X months. Disease Control Rate (DCR) 82.6%. We are getting data sometime in the next X months. Trust me when I say this:"
X Link @BIOTECHSCANNER 2025-10-14T21:52Z 7517 followers, 2716 engagements
"@SMAC1945 Definitely not. Actually Prasad and Makary make me more bullish on $IOVA. THEY are constantly in communication with the FDA. Many people who are approving cancer drugs right now were hired by Dr. Puri Chief Regulatory Officer at $IOVA"
X Link @BIOTECHSCANNER 2025-10-15T00:30Z 7517 followers, XXX engagements
"@mhelvz12 Nice I definitely believe so. $IOVA will be bought out way before XX years from now. I think X years max"
X Link @BIOTECHSCANNER 2025-10-15T00:38Z 7516 followers, XXX engagements
"$IOVA - What does Amtagvi say to tumor burden Where are you now @IovanceBio"
X Link @BIOTECHSCANNER 2025-10-15T02:31Z 7517 followers, 3490 engagements
"Im going to continue to share your story Chris. On February XX 2024 I tweeted an interview that you did with someone. About XX minutes later the PR from $IOVA announcing approval of Amtagvi. I have been tell people that it doesnt matter if they are investing in Iovance or not they should support the company because someday they or someone they know may need TIL treatment from Iovance. I appreciate you continuing to share your miraculous story. I look forward to seeing you on @TheRealDanSfera podcast hopefully after you get back from NYC"
X Link @BIOTECHSCANNER 2025-10-15T03:45Z 7517 followers, XXX engagements
"$IOVA - The company plans to release interim data on: X. Second Line NSCLC - If data is positive then they will wait for phase X to end and then apply for accelerated approval. Because this phase X is a pivotal trial. The company is using the same process as second line metastatic melanoma. The frontline NSCLC in combination with Pembrolizumab will have a dual purpose just like TILVANCE XXX that is to serve as a confirmatory for full second line NSCLC and accelerated frontline approval as well. A lot of attention is paid toward this data release because the NSCLC market is more than 6x of"
X Link @BIOTECHSCANNER 2025-10-15T13:42Z 7517 followers, 2550 engagements
"$IOVA - This is the one. Amtagvi by itself is worth 5x the current price. That is a conservative estimate btw"
X Link @BIOTECHSCANNER 2025-10-15T14:41Z 7516 followers, 3577 engagements
"@thebrmola Its not even close. Look at the pipeline. $AQST can double from here while $IOVA can XX x from here at minimum because NSCLC would have been approved as well as frontline metastatic melanoma"
X Link @BIOTECHSCANNER 2025-10-15T15:25Z 7517 followers, XXX engagements
"$IOVA - InspiroGene partnership solves this bottleneck. This is what they do. They have oncologists on staff to talk to insurance companies to get treatment authorized. They are experts in the latest treatment guidelines. InspiroGene lets the healthcare providers treat patients and the patients focusing on getting their health and lives back. Fewer prescriptions drop off means more sales of Amtagvi. 💥"
X Link @BIOTECHSCANNER 2025-10-15T17:20Z 7517 followers, 3583 engagements
"$IOVA - Lets hear it from the InspiroGene leader Joe DePinto. With a massive pipeline that Iovance has this partnership is a perfect fit. InspiroGene works with the patients and insurers to get them approved for treatment. With many more patients coming in from community hospitals InspiroGene takes care of all of the logistics from treatment approvals to reimbursement for healthcare providers and hospitals"
X Link @BIOTECHSCANNER 2025-10-15T18:38Z 7517 followers, 2469 engagements
"$IOVA - There are 30000 second line metastatic melanoma patients (8K US+22K exUS) and Amtagvi is the only treatment indicated to treat these patients after chemotherapy radiation ICIs are CTLA-4 failed them. $IOVA only needs to treat XX% of the US patients population in second line metastatic melanoma that is 2000 patients per year and generates over $XXX billion in Amtagvi + Proleukin (IL-2) sales. Now do the math when ex-US approvals arrive. Canada already had approved Amtagvi. Thats just second line metastatic melanoma Now add frontline metastatic melanoma for US and ex-US. We are not"
X Link @BIOTECHSCANNER 2025-10-15T19:30Z 7517 followers, 2776 engagements
"@peter_paone Dont forget to celebrate small victories on our way to the big one"
X Link @BIOTECHSCANNER 2025-10-15T20:45Z 7517 followers, XXX engagements
"$IOVA - Dragon fam. @TheRealDanSfera and I have a last minute special podcast for you. On this podcast you will get to meet the mucosal melanoma survivor named Chris White who wrote the book Killing Cancer With TILs. This will be an all out IOVA focused podcast. We will cover everything from the patient perspective to clinical trials and the business case for Iovance. It will be at 7:30 Pm EST 6:30 CT and 4:30 PST. I am beyond pumped Hope you can join"
X Link @BIOTECHSCANNER 2025-10-15T21:03Z 7517 followers, 2578 engagements
"@BioSpaceInvestr @MucosalMelanoma Nice 10k shares is a great I agree with you. $IOVA will succeed because the treatment is amazing and saves lives"
X Link @BIOTECHSCANNER 2025-10-16T03:07Z 7517 followers, XXX engagements
"$IOVA - Shorts will want you to focus on the toxicity of the treatment with Amtagvi. But yesterday you heard from the patient Chris White yourself. The toxicity of the previous lines of treatment (chemotherapy radiation checkpoint inhibitors) that he is still dealing with on a daily basis. He said none of the parts of the Amtagvi treatment regimen side effects bother him after the treatment was done. Its the OTHER previous treatments that is STILL HURTING HIM. @MucosalMelanoma can reconfirm with me here. Amtagvi is the MOST EFFECTIVE TREATMENT in second line metastatic melanoma. PERIOD"
X Link @BIOTECHSCANNER 2025-10-16T13:32Z 7517 followers, 3073 engagements
"@Storm28799 They will not sell $IOVA for less than $X billion. The longer they wait the more they will have to pay if Amtagvi sales increase and new indications coming like NSCLC"
X Link @BIOTECHSCANNER 2025-10-17T14:33Z 7517 followers, XXX engagements
"Thanks for your kind compliments. Your analysis in this video is fair and honest. This is exactly what we want. The information has to meet the standard of accuracy as much as possible and you did a great job The only thing I want to point out is that $IOVA headquarters is in San Carlos California and the Iovance Cell Therapy Center (iCTC) is in Philadelphia Pennsylvania. This is where T cells are shipped to. Thank you for your contribution to the biotech investment community. Its fun to win; its a blast to win together (Patients+Company+Investors) F shorts"
X Link @BIOTECHSCANNER 2025-10-18T16:30Z 7517 followers, XXX engagements
"@proudghanaman Yep One of my favorite Mortal Kombat characters"
X Link @BIOTECHSCANNER 2025-10-18T22:46Z 7517 followers, XXX engagements
"@theRodgerRoundy Very nice Absolute free gifts at these levels. I pounded the table when $AQST was below $X and look where its at. This will go ballistic in the next couple of months"
X Link @BIOTECHSCANNER 2025-10-15T18:12Z 7517 followers, XXX engagements
"$IOVA - I hope you know I dont randomly make up stuff. I spend a lot of time doing research. I read constantly to keep up with the latest developments in medicine and biotech. Why Has nothing to do with investing. Its my love for science and medicine to be more specific. I have done this way before I started investing. So every thing I posted on any biotech company is done with my research and understanding. Am I right all the time Probably not. But most of the time Based on my track record Hell yes I dont take the responsibility lightly because it involves money. I understand the risks and"
X Link @BIOTECHSCANNER 2025-10-16T23:19Z 7518 followers, 2565 engagements
"$IOVA - X companies that may acquire Iovance Biotherapeutics. X. $MRK (Merck) X. $BMY (Bristol Myers) X. $AZN (AstraZeneca) These X have extensive oncology portfolios. $AZN recently has been extremely aggressive to get into cell and gene therapy. $MRK and $BMY have checkpoint inhibitors that would go very well with Amtagvi and future TIL products in $IOVAs pipeline"
X Link @BIOTECHSCANNER 2025-09-29T05:00Z 7518 followers, 8611 engagements
"$GSRT - By the way this is now my biggest position in the portfolio. Even bigger than $IOVA and I have a lot there. $AQST is in third place. This is the new three headed monster. To a bright future 🚀. Patience 🤑. I cant wait to see $NKLR on the list. Love the ticker symbol"
X Link @BIOTECHSCANNER 2025-09-29T20:54Z 7518 followers, 3755 engagements
"$IOVA - Warning to shorts. Your days are numbered1.NSCLC data X. Endometrial cancer data X. Next Generation TIL IOV-4001 data in 2L melanoma X. Possible approval marketing authorization for Amtagvi in Switzerland or approval application submission X. Solid Q3 earnings"
X Link @BIOTECHSCANNER 2025-10-09T13:35Z 7518 followers, 2688 engagements
"@Cricket99238 $IOVA will be at least a $20Bn company. It will actually be bought out before 2026 is over by Merck Bristol Myers or AstraZeneca"
X Link @BIOTECHSCANNER 2025-10-09T22:50Z 7518 followers, XXX engagements
"$IOVA - Cell & Gene Therapy is the hottest sector within biotech. Today Bristol Myers Squibb acquired Orbital Therapeutics that has CAR-T assets for autoimmune diseases. I have said it many times I believe Iovance will be acquired at some point by big pharma. Especially if the NSCLC data is positive in second line. I believe the data will be very positive. In frontline NSCLC using Amtagvi and Pembrolizumab (Keytruda) its already shown incredible efficacy and durability. Patience"
X Link @BIOTECHSCANNER 2025-10-10T14:25Z 7518 followers, 3229 engagements
"$IOVA - Last week I said this (post attached below). Today the FDA did exactly what I had predicted. They widened the definition including non-rare diseases. The FDA announced the first group that may qualify for the new National Priority Review Voucher Program. One drug that the FDA intends to grant the voucher to is for pancreatic cancer due to the large unmet need. This is amazing news for $IOVA. Why In 2025 there are approximately 52K pancreatic cancer deaths in the US. In NSCLC there are 125K deaths per year in the US This is why I said that if data for NSCLC is positive $IOVA will apply"
X Link @BIOTECHSCANNER 2025-10-17T00:54Z 7517 followers, 4251 engagements
"Thank you my friend I really appreciate you donating to St. Jude. Im actually going to do something extra for them if $IOVA and $AQST turn out well. $AQST is almost there and $IOVA will actually surpass it soon. I love these X. $NKLR has become a meme like ticker. I will let it chill for a bit"
X Link @BIOTECHSCANNER 2025-10-17T05:04Z 7518 followers, XXX engagements
"Treatment price is not prohibitive. If the patient has insurance it will be covered if Amtagvi is on that particular plan. Did you hear that after they increased the price from $515K to $560K sales increased I have done this a long time. These treatments are for insurance only. No one can afford paying cash. The company knows this. If the patient needs treatment there is a patient assistance program. Management addressed margin improvements and it is related to the community hospitals becoming ATCs. Healthier patients come from these hospitals. Healthier patients improve TIL quality thus"
X Link @BIOTECHSCANNER 2025-10-20T17:11Z 7518 followers, XX engagements
"$IOVA - What makes Amtagvi unique Why can it destroy cancer cells in solid tumors that CAR-T cant Because the T-cells in Amtagvi are REACTIVE T-cells. Whats that mean TIL (Tumor Infiltrating Lymphocytes) are harvested from at least a 1.5cm of tumor tissue. These lymphocytes already infiltrated or entered the tumor and fighting in the tumor micro environment. These lymphocytes already REACTED or RECOGNIZED the cancer cells whereas in CAR-T the T lymphocytes are collected from the peripheral blood. These T-cells could have been watching Monday Night Football when they were gathered then"
X Link @BIOTECHSCANNER 2025-10-08T17:14Z 7517 followers, 3127 engagements
"$IOVA - Did you know in 2nd Line Metastatic Melanoma Non-Small Cell Lung Cancer (NSCLC) and Endometrial Cancer THERE IS NO EFFECTIVE TREATMENT and patients only have months to live Immune Checkpoint Inhibitors like Keytruda (pembrolizumab) an anti-PD-1 and Yervoy (ipilimumab) a CTLA-4 were initially indicated for second line after chemotherapy and radiation but since had been moved into frontline. Still XX% or more see their cancers progressed or got worse. Now theres only chemo and other drugs combined to help but they are not effective. Then comes badass Amtagvi. In the pivotal phase 2"
X Link @BIOTECHSCANNER 2025-10-11T03:03Z 7517 followers, 4004 engagements
"$IOVA - I posted this earlier but it deserves to be mentioned again. In a $370B market of cellular therapy where Iovance Biotherapeutics has a monopoly in TIL. First with melanoma then potentially NSCLC and endometrial cancer. After that next generation TIL like IOV - 4001 PD-1 inactivated and IOV- 5001 IL-12 tethered TIL will open doors to other solid cancers like breast and head and neck. Next generation IL-2 if still needed is also in clinical trial as well. And youre worried about pennies We dont have enough shares of this company 🐉"
X Link @BIOTECHSCANNER 2025-10-15T15:35Z 7517 followers, 2462 engagements
"$IOVA $AQST -"
X Link @BIOTECHSCANNER 2025-10-15T20:36Z 7517 followers, 2858 engagements
"$IOVA - I will be using this checklist for $IOVA during the podcast today. This is pinned on my profile. There are quite a few potential investors in $IOVA so I have to kind of going back over the fundamentals. X. Undervalued (low market cap vs assets and market potential)✅ X. Solid management (biotech experience CEO track record and reputation not too many turnovers)✅ X. Great pipeline versus whats currently available (look for first and only or best in class potential.✅ X. Solving a big unmet need ✅ X. Incremental successes through various stages of clinical trials ✅ X. Strong upcoming"
X Link @BIOTECHSCANNER 2025-10-15T22:52Z 7517 followers, 2909 engagements
"$IOVA - This is X of the latest innovative potential treatment in second line melanoma using mRNA-4359 in combination with Keytruda. This was posted by Targeted Oncology X hours ago. This treatment involves multiple injections Results: ORR: XX% WITH KEYTRUDA In a PD-1 positive population which is an easier to treat than PD-1/PD-L1 negative population. Amtagvi by itself in phase X : ORR XXXX% mDOR XXXX months with twice the number of patients with PD-L1 negative of XX% and PD-1 positive 33%. Again PD-1/PD-L1 negative is harder to treat. Then a X year real world retrospective physician assessed"
X Link @BIOTECHSCANNER 2025-10-16T21:15Z 7517 followers, 3504 engagements
"$IVF - I thought I probably had to take a loss for tax purposes but now will get more $IOVA. Patience 🤑always wins"
X Link @BIOTECHSCANNER 2025-10-16T21:20Z 7517 followers, 2406 engagements
"$IOVA - If interim phase X data for NSCLC being released anytime in Q4 is positive I believe theres almost a XXX% chance that Amtagvi will get the National Priority Review Voucher cutting FDA decision from 6-10 months to 1-2 months after the final data arrives several months later. The innovation of TIL therapys X time treatment and a massive unmet need in second line NSCLC makes perfect sense for the FDA to grant Amtagvi the priority voucher. After this frontline metastic melanoma in combination with Pembrolizumab in TILVANCE XXX is on deck. Then frontline NSCLC in combination with"
X Link @BIOTECHSCANNER 2025-10-17T02:59Z 7517 followers, 2342 engagements
"$IOVA - What is Amtagvi(lifileucel) It is the first ever TIL cell therapy treatment indicated for second line metastatic melanoma. These patients after first line treatments failed have no options besides more ineffective and punishing chemotherapy in combination with other drugs that already been used AND FAILED like Keytruda and Yervoy from the powerful class of drugs called checkpoint inhibitor. Then comes Amtagvi. In clinical trials it showed Objective Response Rate (ORR) XXXX% and median Duration of Response (mDOR)36.5 months. Remember these patients only have months and are more often"
X Link @BIOTECHSCANNER 2025-10-17T13:52Z 7517 followers, 2235 engagements
"$IOVA - We all have the opportunity to load at this bottomed out level. With the up coming catalysts shorts that piled in are at the mercy of the company as to when and how they will release the PRs. The company already said they will publish data in a peer review journal for maximum credibility and exposure. It is more time consuming and expensive but wanted to have stricter standards and more respect to the data. After that they will release via PR. No dates have been set. PRs may be released on any given day between today and the end of the year. Theres not many trading weeks left All of"
X Link @BIOTECHSCANNER 2025-10-17T16:33Z 7517 followers, 2275 engagements
"$IOVA - When theres no hope left for patientsTheres Amtagvi @IovanceBio @MucosalMelanoma"
X Link @BIOTECHSCANNER 2025-10-17T18:50Z 7517 followers, 1750 engagements
"$IOVA - @Merck Your Iovance Biotherapeutics and you can team up to defeat solid cancers like in the Frontline metastatic melanoma study TILVANCE XXX right now. You dont have to look very far. If not AstraZeneca will. @IovanceBio"
X Link @BIOTECHSCANNER 2025-10-17T20:19Z 7517 followers, 1078 engagements
"$IOVA - You may notice that the company probably will not release ANY clinical trials data at upcoming conferences. This is EXACTLY what we want. Iovance wants to publish data in a peer reviewed journal. It is more expensive and time consuming BUT if they want to destroy shorts this is how to do it. Publish data in peer reviewed journal and send it via PRs through numerous news outlets. Dr. Brian Gastman EVP Medical Affairs talked about how the company is going to be releasing data during the Wells Fargo Healthcare Conference on September X 2025. After releasing data via PRs the company will"
X Link @BIOTECHSCANNER 2025-10-17T20:57Z 7517 followers, 2505 engagements
"$IOVA - My notifications just bing and I thought a PR was released 😆. It for inducement grants. Which is bullish by the way. X new employees"
X Link @BIOTECHSCANNER 2025-10-17T21:20Z 7517 followers, 2212 engagements
"$IOVA - ATTENTION 🐉🐉🐉😀. Data for NSCLC endometrial cancer and IOVA 4001 in second line metastatic melanoma will be released via Press Releases (PRs) as stated by Dr. Brian Gastman EVP Medical Affairs. Data will be released by end of year. Hes in charge of all things related to clinical trials at Iovance Biotherapeutics. He wants data to be published in a prestigious scientific journal that is peer reviewed. This is exactly what every company wants if they have ground breaking or breakthrough data in areas with large unmet needs. Non-Small Cells Lung Cancer (NSCLC) endometrial cancer and"
X Link @BIOTECHSCANNER 2025-10-18T17:34Z 7517 followers, 2584 engagements
"$IOVA - Its such perfect timing when @IovanceBio released the poster that will be presented at European Society for Medical Oncology Congress 2025 one of the largest and most influential annual oncology meetings in the world similar in importance to ASCO and SITC. The poster titled Evaluating curative potential of lifileucel in previously treated advanced melanoma: Analyses from C-144-01 Trial Think about this: For patients who progressed from frontline to second line metastatic melanoma after previous treatments like chemotherapy and immune checkpoint inhibitors have failed them. These"
X Link @BIOTECHSCANNER 2025-10-18T20:44Z 7517 followers, 1850 engagements
"$IOVA - This isnt competition on efficacy. Its competition for attention. Amtagvi will win on both fronts. The world is beginning to recognize the power of a X time treatment with unsurpassed efficacy and durability. Conviction through science backed research. I got you covered. Its good that we talk about it"
X Link @BIOTECHSCANNER 2025-10-18T21:47Z 7517 followers, 4163 engagements
"$IOVA - When I decided to use my biology background and pharmaceutical experience to find biotech and tech companies to invest in I began with a checklist. Its pinned to my profile. The current one was updated a year and X months ago. I may tweak it again but it still looks exactly as I wanted it. I am going to use the checklist on $IOVA and fill in the details as to why it gets a check mark on each item. How to identify great biotech companies: $IOVA X. Undervalued (low market cap vs assets and market potential)✅ The current share price (SP) is $XXXX market cap (MC)is at $788M. The MC is"
X Link @BIOTECHSCANNER 2025-10-20T02:15Z 7517 followers, 2954 engagements
"$IOVA - Other potential treatments can only dream. Nothing is better than Amtagvi X time treatment. This is X year REAL WORLD EVIDENCE that the new FDA loves"
X Link @BIOTECHSCANNER 2025-10-20T13:29Z 7517 followers, 2517 engagements
"$IOVA - I saw REPL got their BLA resubmission accepted by the FDA. They received a CRL in July. A new PDUFA date is set for April XX 2026. I am not sure if they have addressed all of the concerns from the FDA in this application. Approval is 50/50 at best. REPL received a CRL because: X. The supporting Phase 1/2 IGNYTE trial was not an adequate and well-controlled clinical investigation per the FDAs determination. 2.The patient population in IGNYTE was too heterogeneous which limited interpretability of the data. 3.The ongoing confirmatory trial (IGNYTE-3) had design issues especially around"
X Link @BIOTECHSCANNER 2025-10-20T13:41Z 7517 followers, 1969 engagements
"$IOVA - The company continues to invest in its business and future. It could easily become profitable with Amtagvi alone. It is investing massively in its future business with XX clinical trials in solid cancers and blood cancers as well as well as new generation TIL and IL-2. The concerns of the large R&D expenses will be squashed soon with new data on NSCLC that will be used to apply for the newly created National Priority Voucher. This qualifies Amtagvi for a 1-2 month review for accelerated approval. There is more than 10000 patients died of NSCLC per month in the US. You think this is"
X Link @BIOTECHSCANNER 2025-10-20T13:55Z 7517 followers, 2217 engagements
"$IOVA - Checklist #2 X. Solid management (biotech experience CEO track record and reputation not too many turnovers)✅ After the slower than forecasted Amtagvi launch management made some big changes. X. New Chief Commercial Officer- Dan Kirby. Immediately after arriving at Iovance implements key initiatives to drive early Amtagvi adoption that will help speed up sales tremendously over time. Namely the inclusion of community hospitals as their own authorized treatment centers (ATCs) and partnership with InspiroGene by McKesson. InspiroGene to provide services such logistics for treatment"
X Link @BIOTECHSCANNER 2025-10-20T15:23Z 7517 followers, 1874 engagements
"$IOVA - Im telling you right now the new NSCLC data will be transformative for the patients and the company. With the massive unmet need in this deadly cancer Amtagvi will qualify for the new priority review voucher. The review timeframe will be 1-2 months after the sBLA is accepted. Need further evidence The FDA is going to cut down the approval timeline for all drugs in the future as well This is amazing for biotech and patients"
X Link @BIOTECHSCANNER 2025-10-20T15:44Z 7517 followers, 3791 engagements
"$IOVA $AQST - Tomorrow at X pm ET X pm CST and 3pm PST"
X Link @BIOTECHSCANNER 2025-10-20T16:06Z 7517 followers, 2996 engagements
"@n_hatami I would take shares as payments Thank you brother"
X Link @BIOTECHSCANNER 2025-10-20T17:15Z 7518 followers, XX engagements
"$IOVA - Checklist #3 How to identify great biotech companies. X. Great pipeline versus whats currently available (look for first and only or best in class potential.✅ This is probably the easiest one Amtagvi is the ONLY treatment specifically indicated to treat second line metastatic melanoma. THERES NOTHING ELSE except more ineffective chemotherapy in combination with other immunotherapy that cancer already beat. In the phase X trial where Amtagvi received accelerated approval on February 162024 the results were impressive. ORR XXXX% mDOR XXXX months. Then the company recently released a 5"
X Link @BIOTECHSCANNER 2025-10-20T19:57Z 7517 followers, 2047 engagements
"$IOVA - You think Iovance Therapeutics may be a hot commodity after positive data being released by the end of this year Here are the data we are waiting on: X. 2L Non-Small Cell Lung Cancer (NSCLC). X. 2L Endometrial Cancer X. 2L metastatic melanoma using next generation TIL IOV 4001 (genetically engineered PD-1 inactivated). This is like Amtagvi with Keytruda 💥. Look who just threw in the towel trying to develop advanced melanoma vaccine"
X Link @BIOTECHSCANNER 2025-10-20T22:21Z 7517 followers, 2302 engagements
"@RosenzweigDMD X. Merck X. BMY X. AstraZeneca"
X Link @BIOTECHSCANNER 2025-10-21T01:12Z 7517 followers, XXX engagements